WO2004007711A1 - 新規蛋白質およびその用途 - Google Patents
新規蛋白質およびその用途 Download PDFInfo
- Publication number
- WO2004007711A1 WO2004007711A1 PCT/JP2003/008690 JP0308690W WO2004007711A1 WO 2004007711 A1 WO2004007711 A1 WO 2004007711A1 JP 0308690 W JP0308690 W JP 0308690W WO 2004007711 A1 WO2004007711 A1 WO 2004007711A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- protein
- present
- salt
- polynucleotide
- partial peptide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- the present invention relates to a novel secreted or membrane protein derived from mouse white adipocytes or a salt thereof, a DNA encoding the same, and uses thereof.
- Obesity with visceral fat accumulation has a high probability of vascular disease such as diabetes, hypertension, and atherosclerosis, and visceral fat accumulation is considered to be a common basis for triggering the actual onset of pathological conditions. It is possible that proteins produced by fat cells may be involved in the pathogenesis of fat accumulation.However, genes expressed in adipose tissue have a high frequency of secretory protein genes, including complement and complement. It has been shown to contain genes for physiologically active substances such as growth factors. Such a substance
- Adipocytokine also called adipocytokine
- Adipocytokine naturally plays an important role in the metabolism of fat cells themselves, but it is possible that hypersecretion or, conversely, deficiency in secretion during fat accumulation may adversely affect the metabolism of the whole individual.
- PA I-1 plasminogen activator overnight inhibitor 1
- adipose most abundant gene transcript-1 which is specifically and frequently expressed in adipose tissue, encodes a collagen-like protein (adiponect in), and this substance is present in large amounts in human blood. Although it has the effect of strongly inhibiting the proliferation of vascular smooth muscle cells, it has been shown that blood levels in obese people are conversely reduced, leading to vascular disease [Arita, Y.] "Biochemical 'and' Biophysical Research Communications (Biochem. Biophys. Res. Commun.) ", (USA), Vol. 257 (No. 1), pp. 79-83 (1999)].
- Adipocytes also synthesize large amounts of fat and actively degrade lipolysis, releasing fatty acids and glycerol into the blood.
- the membrane protein aquaporin adipose cloned by Kuriyama et al. Is used as a glycerol channel molecule in adipocytes. [Kishida, K. et al., J. Biol. Chemistry, (USA), Vol. 275 (No. 27) No.), pp. 20896-20902 (2000)].
- adipocytes secrete various biologically active substances (ie, ligands), and express membrane proteins (ie, receptors) on the cell surface. Therefore, regulation of the expression or biological activity of these secretory membrane proteins may lead to the development of novel methods for preventing and treating obesity, diabetes, and vascular diseases (eg, arteriosclerosis). Be expected.
- the present invention may be a useful tool for developing preventive and therapeutic drugs for obesity, diabetes, arteriosclerosis, etc., or a useful diagnostic marker for these diseases.
- the purpose of the present invention is to identify novel secretory and membrane protein genes specifically or highly expressed in adipocytes.
- the present invention provides a recombinant vector containing the novel gene, a transformant carrying the recombinant vector, a method for producing the secretory membrane protein by culturing the transformant, and a secretory membrane protein.
- the present inventors prepared a cDNA library derived from visceral adipose tissue of a high-fat diet-loaded mouse, and deleted the cDNA from the N-terminal extracellular region.
- Constitutively active trombopoietin receptor (serine at position 498 is replaced by asparagine) c.
- Construction of retrovirus expression library integrated into 5 'side of DNA, high titer from packaging cells The retrovirus was recovered, infected with a mouse proB cell line (BaZF3), and cells that maintained proliferation were selected. Genomic DNA was extracted from the selected cells, and the introduced mouse adipocyte-derived cDNA was subcloned using PCR, and its nucleotide sequence was determined.
- cDNA clones containing the full length of the protein coding region were isolated from mouse adipocyte-derived cDNA, and their nucleotide sequences were determined. I knew it was a gene.
- [1] a protein comprising the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 2, a partial peptide thereof, or a salt thereof;
- [5] a protein comprising the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 4, a partial peptide thereof, or a salt thereof;
- a protein comprising the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 8, or a partial peptide thereof or a salt thereof;
- [17] a protein comprising the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 10, a partial peptide thereof, or a salt thereof;
- a protein comprising the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 12, or a partial peptide thereof, or a salt thereof; [22] a base encoding the protein or partial peptide according to the above [21] A polynucleotide comprising the sequence;
- polynucleotide or processing result of the polynucleotide described in [22] above A polynucleotide comprising a nucleotide sequence complementary to the initial transcript resulting from the polynucleotide or a part thereof;
- a protein comprising the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 14, or a partial peptide thereof, or a salt thereof; [26] a base encoding the protein or partial peptide according to the above [25] A polynucleotide comprising the sequence;
- a protein comprising the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 16, or a partial peptide thereof, or a salt thereof; [30] a base encoding the protein or partial peptide according to the above [29] A polynucleotide comprising the sequence;
- polynucleotide according to the above-mentioned [30] the polynucleotide according to the above-mentioned [30], or a polynucleotide comprising a nucleotide sequence complementary to the initial transcript or a part thereof which results in the polynucleotide as a result of processing;
- a protein comprising the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 18, or a partial peptide thereof, or a salt thereof; [34] a base encoding the protein or partial peptide according to the above [33] A polynucleotide comprising the sequence;
- a protein comprising the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 20, or a partial peptide thereof or a salt thereof; [38] encoding the protein or partial peptide according to the above [37] A polynucleotide comprising a base sequence;
- a protein comprising the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 22 or a partial peptide thereof or a salt thereof; [42] the protein or the partial peptide of the above-mentioned [41] is encoded; A polynucleotide comprising a base sequence;
- a medicament comprising the protein according to [25], [29], [33], [37] or [41], or a partial peptide thereof or a salt thereof;
- a diagnostic agent comprising:
- a medicament comprising an obtainable compound or a salt thereof;
- a medicament comprising a compound or a salt thereof obtainable by using the method of the above-mentioned [58] or the kit of the above-mentioned [59];
- a medicament comprising a compound or a salt thereof obtainable by using the method of the above-mentioned [62] or the kit of the above-mentioned [63];
- the protein of the present invention is a secretory or membrane protein expressed in white adipocytes upon a high fat diet load, it can be used as a preventive or therapeutic agent for diseases associated with adipocyte differentiation or abnormal metabolic function, or It has an excellent effect as a tool for screening candidate drug compounds that are effective for the prevention and treatment of the disease.
- the present invention relates to secretory or membrane proteins specifically or highly expressed in white adipose tissue of humans or other mammals loaded with a high-fat diet (hereinafter referred to collectively as “proteins of the present invention”. Yes) is provided.
- the protein of the present invention is a protein containing an amino acid sequence identical or substantially identical to the amino acid sequence represented by SEQ ID NO: 2 (hereinafter referred to as “SST20-14 (Long form) j
- a protein containing an amino acid sequence identical or substantially identical to the amino acid sequence represented by SEQ ID NO: 4 hereinafter, also referred to as “SST20-14 (Shortfonn)”
- SEQ ID NO: 6 A protein containing the same or substantially the same amino acid sequence as the represented amino acid sequence (hereinafter also referred to as “SST22-22 (Long form)”); identical or substantially identical to the amino acid sequence represented by SEQ ID NO: 8
- SEQ ID NO: 8 A protein containing the same amino acid sequence (hereinafter also referred
- a protein comprising an amino acid sequence identical or substantially identical to the amino acid sequence represented by SEQ ID NO: 18 (hereinafter, also referred to as “SST9-8”); represented by SEQ ID NO: 20
- a protein containing the same or substantially the same amino acid sequence as the amino acid sequence (hereinafter sometimes referred to as “SST2 3”); or the same or substantially the same as the amino acid sequence represented by SEQ ID NO: 22 Containing identical amino acid sequences (Hereinafter also referred to as “SST20-6”).
- the protein of the present invention is a secretory or membrane protein highly expressed in adipose tissue of mammals, particularly white adipose tissue, but is not particularly limited in its origin as long as it has the above-mentioned properties.
- Human, mouse, rat, egret, sheep, pig, pig, dog, cat, dog, monkey, chimpanzee, etc. Human, mouse, rat, egret, sheep, pig, pig, dog, cat, dog, monkey, chimpanzee, etc.
- hepatocytes hepatocytes, spleen cells, nerve cells, glial cells, brain cells
- bone marrow cells mesangial cells, Langerin's cells, epidermal cells, epithelial cells, goblet cells, endothelial cells, smooth muscle cells, fibers Blast cells, fiber cells, muscle cells, fat cells, immune cells (eg, macrophages, T cells, B cells, natural killer cells, mast cells, neutrophils, basophils, eosinophils, monocytes), megakaryocytes , Synovial cells, chondrocytes, bone cells, osteoblasts, osteoclasts, mammary cells, hepatocytes or stromal cells, or progenitor cells, stem cells or cancer cells of these cells] or their cells Any tissue [e.g., hepatocytes, spleen cells, nerve cells, glial cells, brain cells) 3 cells, bone marrow cells, mesangial cells, Langerin's cells, epiderma
- brain parts of the brain (eg olfactory bulb, amygdala, basal sphere, hippocampus, thalamus, hypothalamus, cerebral cortex, medulla, cerebellum), spinal cord, pituitary, stomach, kidney, kidney, liver Gut, gonad, thyroid, gallbladder, bone marrow, adrenal gland, skin, lung, digestive tract (eg, large intestine, small intestine), blood vessels, heart, thymus, spleen, submandibular gland, peripheral blood, prostate, testicle, ovary, placenta, uterus , Bone, joints, adipose tissue (eg, brown adipose tissue, white adipose tissue), skeletal muscle, etc.].
- adipose tissue eg, brown adipose tissue, white adipose tissue
- skeletal muscle etc.
- a protein biochemically synthesized by chemical synthesis or a cell-free translation system Or a recombinant protein produced from a transformant into which a nucleic acid having a nucleotide sequence encoding the above amino acid sequence has been introduced.
- substantially identical amino acid sequence the amino acid sequence represented by each of the above SEQ ID NOs (SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 20 or 22) And about 70% or more, preferably about 80% or more, more preferably about 90% or more, and particularly preferably about 95% or more.
- homoology refers to an optimal alignment (preferably, the algorithm is optimized for optimal alignment) when two amino acid sequences are aligned using a mathematical algorithm known in the art. (Which may take into account the introduction of gaps in one or both of the sequences), the percentage of identical and similar amino acid residues to all overlapping amino acid residues.
- Similar amino acids means amino acids that are similar in physicochemical properties, such as aromatic amino acids (Phe, Trp, Tyr), aliphatic amino acids (Ala, Leu, Ile, Val), and polar amino acids (Gln , Asn), basic amino acids (Lys, Arg, His), acidic amino acids (Glu, Asp), amino acids with hydroxyl groups (Ser, Thr), amino acids with small side chains (Gly, Ala, Ser, Thr, Met) And other amino acids classified in the same group. It is expected that substitutions with such similar amino acids will not change the phenotype of the protein (ie, conservative amino acid substitutions).
- the ⁇ substantially identical amino acid sequence '' is about 60% or more, preferably about 70% or more, more preferably about 80% or more, Particularly preferred are amino acid sequences having about 90% or more identity.
- protein containing substantially the same amino acid sequence examples include, for example, a protein containing the aforementioned “substantially identical amino acid sequence” and containing the amino acid sequence represented by each of the above SEQ ID NOs. Proteins having substantially the same activity are preferred.
- the “substantially the same activity” includes, for example, a receptor binding activity (or ligand) binding activity and a signal transduction activity. “Substantially equivalent” indicates that their activities are qualitatively (eg, physiologically or pharmacologically) equivalent. Therefore, it is preferable that the activities such as the receptor binding activity (ligand) and the signaling activity are equivalent (eg, about 0.5 to about 2 times), but the degree of these activities, the molecular weight of the protein, etc. The quantitative elements of may be different.
- Activity such as receptor (or ligand) binding activity and signal transduction activity can be measured in accordance with a method known per se.
- Ligands can be measured according to the methods used in screening methods for agonists and antagonists.
- Examples of the protein of the present invention include: (1) one or more or more amino acid sequences represented by the above-mentioned SEQ ID NOs (preferably, about 1 to 30, preferably about 1 to 10) More preferably, an amino acid sequence in which a number (1 to 5) of amino acids have been deleted.
- One or more amino acids preferably about 1 to 30, preferably An amino acid sequence to which about 1 to 10 amino acids have been added, and more preferably a number (1 to 5) of amino acids; and 3) one or two or more amino acids (preferably 1 to 30) An amino acid sequence into which about, preferably about 1 to 10, and more preferably a number (1 to 5) amino acids have been inserted; 1 one or more of the amino acid sequences represented by the above-mentioned SEQ ID NOs.
- about 1 to 30, preferably 1 to 10 A protein comprising an amino acid sequence in which the number of amino acids has been replaced by another amino acid, and more preferably a number (1 to 5) of amino acids, or a combination thereof.
- proteins having substantially the same activity as the protein containing the amino acid sequence represented by the number is as defined above.
- the position of the insertion, deletion or substitution is not particularly limited as long as the activity of the protein is maintained.
- the protein of the present invention is a secreted or membrane protein, which is usually translated in vivo as a precursor polypeptide having a signal peptide at the N-terminus, and then processed by signal peptidase to form a mature (or pro) protein.
- a mature (or pro) protein Becomes The cleavage site of the signal peptide (N-terminus of the mature (pro) protein) can be determined, for example, by subjecting the completely or partially purified protein of the present invention to the Edman degradation method. Can be predicted using a known mathematical algorithm. Examples of such an algorithm include the algorithm described in Nielsen et al., Int. Neural Syst., 8 (5-6): 581-599 (1997) [The algorithm is a SignalP program (WWW server: http: ⁇ www).
- the polypeptide having the amino acid sequence represented by each of the above SEQ ID NOs: Is expected to be cleaved between Does not always correspond to the actual cleavage site, and the signal cleavage position may vary depending on the cell type expressing the protein of the present invention.
- the protein of the present invention is preferably a mouse SST20-14 (Long form) having the amino acid sequence represented by SEQ ID NO: 2, a mouse SST20-14 (Short form) having the amino acid sequence represented by SEQ ID NO: 4 SST22-22 (Long form) having the amino acid sequence represented by SEQ ID NO: 6, mouse SST22-22 (Short form) having the amino acid sequence represented by SEQ ID NO: 8, represented by SEQ ID NO: 10
- Mouse SST8-5 having the amino acid sequence represented by SEQ ID NO: 12, mouse SST19-15 having the amino acid sequence represented by SEQ ID NO: 12 (Long form), mouse SST19- having the amino acid sequence represented by SEQ ID NO: 14 15 (Short form), mouse SST13-11 having the amino acid sequence represented by SEQ ID NO: 16, mouse SST9-8 having the amino acid sequence represented by SEQ ID NO: 18, represented by SEQ ID NO: 20
- Mouse SST2 having an amino acid sequence or represented by SEQ ID NO: 22 Is their homologs in mice SST20
- proteins and peptides are described according to the convention of peptide labeling, with the left end being the N-terminus (amino terminus) and the right end being the C-terminus (carboxyl terminus).
- the C-terminus has a lipoxyl group (1-COOH), carboxylate (one COO-), ⁇ bromide (- CONH 2), or, as R in the ester good c the ester be any of (-COOR), for example, methyl, Echiru, n _ propyl, isopropyl, n- C i _ 6 alkyl groups such as butyl; for example, C 3 _ 8 cycloalkyl group such as cyclopropyl pentyl, cyclohexyl; for example, phenylene Le, such as single-naphthy
- the protein of the present invention has a lipoxyl group (or carboxylate) other than the C-terminus
- a protein in which the lipoxyl group is amidated or esterified is also included in the protein of the present invention.
- the ester in this case, for example, the above-mentioned terminal ester and the like are used.
- the proteins of the present invention what is Amino groups of the amino acid residues at the N-terminus is protected with a protecting group (e.g., formyl group, etc. Ashiru groups such as C Bok 6 Arukanoiru such Asechiru group), in vivo N-terminal glutamine residue that can be generated by cleavage with a pyroglutamine oxidation, a substituent on the side chain of an amino acid in the molecule (for example, --OH, --SH, amino group, imidazole group, indole group) , Guanijino group, etc.) a suitable protecting group (e.g., formyl groups, C E, such Asechi Le group - such as 6 Arukanoiru C i _ 6 Ashiru group such group) as protected by, a sugar chain bound Complex proteins such as so-called glycoproteins are also included.
- a protecting group e.g., formyl group, etc. Ashiru groups such as C Bok 6 Aru
- partial peptide of the protein of the present invention is a peptide having the partial amino acid sequence of the protein of the present invention, and the protein of the present invention. As long as they have substantially the same activity as Or any one of them.
- substantially the same activity is as defined above.
- the “substantially equivalent activity” can be measured in the same manner as in the case of the protein of the present invention.
- the partial peptide of the present invention for example, of the amino acid sequence represented by each of the above SEQ ID NOs, it binds to a biological substance (receptor or ligand) that can interact with the protein of the present invention.
- a biological substance receptor or ligand
- Those having a partial amino acid sequence that further includes a region involved and a region involved in signal transduction through the interaction are used.
- the partial peptide of the present invention is preferably a peptide having at least 30 or more, preferably 60 or more, more preferably 100 or more amino acids.
- a peptide containing a partial amino acid sequence of the protein of the present invention but not having substantially the same activity as the protein interacts with the protein of the present invention among the amino acid sequences represented by the above SEQ ID NOs.
- Those having a partial amino acid sequence that includes a region involved in binding to a biological substance (receptor or a ligand) that is capable of binding, but does not include a region involved in signal transduction through the interaction are described in the present invention. Not included.
- a peptide can bind to a biological substance (receptor or ligand) capable of interacting with the protein of the present invention and block the signal transduction action of the protein, abnormal enhancement of the signal transduction is involved. It can be useful for preventing and treating pathological conditions and diseases.
- the C-terminus may be any of a hydroxyl group (-COOH), a carboxylate (-C ⁇ -), an amide (_C ⁇ NH 2 ), or an ester (-COOR).
- R in the ester those similar to those described above for the protein of the present invention can be mentioned.
- the partial peptide of the present invention has a carboxyl group (or carboxylate) at a position other than the C-terminus, those in which the lipoxyl group is amidated or esterified are also included in the partial peptide of the present invention.
- the ester in this case, for example, those similar to the C-terminal ester and the like are used.
- the partial peptide of the present invention has, similarly to the above-mentioned protein of the present invention, one in which the amino group of the N-terminal amino acid residue is protected by a protecting group, and one in which the glutamine residue at the N-terminal has undergone pyroglutamine oxidation. And those in which the substituent on the side chain of the amino acid in the molecule is protected with an appropriate protecting group, or complex peptides such as so-called glycopeptides to which a sugar chain is bound.
- Examples of the salt of the protein of the present invention or its partial peptide include a physiologically acceptable salt with an acid or a base, and a physiologically acceptable acid addition salt is particularly preferable.
- Such salts include, for example, salts with inorganic acids (eg, hydrochloric acid, phosphoric acid, hydrobromic acid, sulfuric acid) or organic acids (eg, acetic acid, formic acid, propionic acid, fumaric acid, maleic acid, Salts with succinic acid, tartaric acid, citric acid, malic acid, oxalic acid, benzoic acid, methanesulfonic acid, benzenesulfonic acid) are used.
- inorganic acids eg, hydrochloric acid, phosphoric acid, hydrobromic acid, sulfuric acid
- organic acids eg, acetic acid, formic acid, propionic acid, fumaric acid, maleic acid
- the protein of the present invention or a salt thereof can be produced from the above-described mammalian cells or tissues by a protein purification method known per se. Specifically, when the protein of the present invention is localized in the cell membrane, mammalian tissues or cells are homogenized, and cell debris is removed by low-speed centrifugation. (If necessary, the cell membrane fraction is purified by density gradient centrifugation or the like), and the fraction is subjected to chromatography such as reverse phase chromatography, ion exchange chromatography, affinity chromatography and the like. Thus, the protein or a salt thereof can be prepared.
- the protein of the present invention When the protein of the present invention is secreted extracellularly, after culturing mammalian tissues or cells in an appropriate medium, the culture supernatant is separated by filtration or centrifugation, and the supernatant is separated.
- the protein or its salt can be prepared by chromatography or the like in the same manner as described above.
- protein (peptide) of the present invention may be produced according to a known peptide synthesis method.
- the peptide synthesis method may be, for example, either a solid phase synthesis method or a liquid phase synthesis method.
- Partial peptide or amino acid that can constitute the protein (peptide) of the present invention The desired protein can be produced by condensing the amino acid and the remaining portion and, when the product has a protecting group, removing the protecting group.
- condensation and the elimination of the protecting group are performed according to a method known per se, for example, the methods described in the following 1 to 1.
- the protein (peptide) thus obtained can be purified and isolated by a known purification method.
- the purification method include solvent extraction, distillation, column chromatography, liquid chromatography, recrystallization, and combinations thereof.
- the free form can be converted into an appropriate salt by a known method or a method analogous thereto, and conversely, the protein (peptide) is converted into a salt.
- the salt can be converted to a free form or another salt by a known method or a method analogous thereto.
- resins for protein synthesis include, for example, chloromethyl resin, hydroxymethyl resin, benzhydrylamine resin, aminomethyl resin, 4-benzyloxybenzyl alcohol resin, 4-methylbenzhydrylamine resin, PAM resin, 4-hydroxymethylmethylphenylacetamide methyl resin, polyacrylamide resin, 4- (2 ', 4'-dimethoxyphenyl-hydroxymethyl) phenoxy resin, 4- (2', 4'-dimethoxyphenyl resin — Fmoc aminoethyl) phenoxy resin.
- amino acids having a suitably protected amino group and side chain functional group are condensed on the resin in accordance with the sequence of the target protein (peptide) according to various known condensation methods.
- proteins and the like are cut out from the resin, and at the same time, various protecting groups are removed.
- an intramolecular disulfide bond formation reaction is carried out in a highly diluted solution to obtain a target protein (peptide) or its amide. .
- the condensation of the above protected amino acids various activating reagents that can be used for protein synthesis can be used, and carbodiimides are particularly preferable.
- carbodiimides DCC, N, N'-diisopropylcarboimide, N-ethyl-N '-(3-dimethylaminoprolyl) carbodiimide and the like are used.
- the protected amino acids may be added directly to the resin along with racemization inhibitors (eg, HOB't, HOOBt) or may be added as symmetrical anhydrides or HOBt esters or HOOBt esters. It can be added to the resin after activation of the protected amino acid.
- the solvent used for the activation of the protected amino acid and the condensation with the resin can be appropriately selected from solvents known to be usable for the protein condensation reaction.
- acid amides such as N, N-dimethylformamide, N, N-dimethylacetamide, N-methylvinylidone, halogenated hydrocarbons such as methylene chloride and chloroform, alcohols such as trifluoroethanol , Sulfoxides such as dimethyl sulfoxide, amines such as pyridine, ethers such as dioxane and tetrahydrofuran, nitriles such as acetonitrile and propionitrile, esters such as methyl acetate and ethyl acetate, or an appropriate one of these.
- the reaction temperature is appropriately selected from the range that can be used for the protein bond formation reaction, and is usually selected from the range of about ⁇ 20 to 50.
- the activated amino acid derivative is usually used in a 1.5 to 4-fold excess.
- the protection of the functional group which should not be involved in the reaction of the raw materials, the protecting group, the elimination of the protective group, the activation of the functional group involved in the reaction, and the like can be appropriately selected from known groups or known means.
- Examples of the protecting group for the amino group of the starting material include Z, Boc, tertiary pentoxycarbonyl, isopolnyoxycarbonyl, 4-methoxybenzyloxycarbonyl, CI—Z, Br_Z, and adamantylo.
- Xycarbonyl, trifluoroacetyl, phthaloyl, formyl, 2-nitrophenylsulfenyl, diphenylphosphinothioyl, Fmoc and the like are used.
- the carboxyl group may be, for example, alkyl esterified (eg, methyl, ethyl, propyl, butyl, tertiary butyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 2-adamantyl, etc.) Or cyclic alkyl esterification), aralkyl esterification (eg, benzyl ester, 412 trobenzyl ester, 4-methoxybenzyl ester, 4-cyclobenzyl ester, benzhydryl esterification), phenacyl esterification Benzyloxycarbonyl hydrazide, tert-butoxycarbonyl hydrazide, trityl hydrazide and the like.
- alkyl esterified eg, methyl, ethyl, propyl, butyl, tertiary butyl, cyclopentyl, cyclo
- the hydroxyl group of serine can be protected, for example, by esterification or etherification.
- a group suitable for the esterification for example, a lower alkanol group such as an acetyl group, an aroyl group such as a benzoyl group, a group derived from carbonic acid such as a benzyloxycarponyl group, an ethoxycarbonyl group, and the like are used.
- Examples of a group suitable for etherification include a benzyl group, a tetrahydrovinyl group, a t-butyl group, and the like.
- the protecting group of the phenolic hydroxyl group of tyrosine for example, B z and C 1 2 - B z 1, are needed use 2-nitrobenzyl, B r _ Z, such as tertiary butyl.
- Examples of the protecting group for histidine imidazole include Tos, 4-methoxy2,3,6-trimethylbenzenesulfonyl, DNP, and benzyloxy. Cimethyl, Bum, Boc, Trt, Fmoc and the like are used.
- the acid treatment for example, anisol, phenol, thioanisole, meth-cresol, para-cresol, dimethyl sulfide, 1,4-butanedithiol, It is effective to add a cation scavenger such as 1,2 monoethanedithiol, etc. Also, imidazole preservation of histidine is effective.
- the 2,4-dinitrophenyl group used as a protecting group is removed by thiophenol treatment, and the formyl group used as an indole protecting group for tributofan is the presence of 1,2-ethanedithiol and 1,4-butanedithiol as described above. In addition to the deprotection by acid treatment below, it is also removed by an alkaline treatment with dilute sodium hydroxide solution, dilute ammonia and the like.
- Examples of the activated carbonyl group of the raw material include, for example, corresponding acid anhydrides, azides, active esters [alcohols (eg, pentachlorophenol, 2,4,5-trichlorophenol, 2,4 —Dinitrophenol, cyanomethyl alcohol, paranitrophenol, H ⁇ NB, N-hydroxysuccinimide, N-hydroxyphthalimide, ester with HOB t)].
- active esters eg, pentachlorophenol, 2,4,5-trichlorophenol, 2,4 —Dinitrophenol, cyanomethyl alcohol, paranitrophenol, H ⁇ NB, N-hydroxysuccinimide, N-hydroxyphthalimide, ester with HOB t
- the activated amino group of the raw material for example, a corresponding phosphoric amide is used.
- a peptide chain is extended to a desired chain length on the amino group side.
- a protein (peptide) from which only the protecting group for the amino group at the N-terminal of the peptide chain was removed and a protein (peptide) from which only the protecting group for the carboxyl group at the C-terminus were removed, Both The protein (peptide) is condensed in a mixed solvent as described above. Details of the condensation reaction are the same as described above.
- the protected protein (protected peptide) obtained by the condensation After purifying the protected protein (protected peptide) obtained by the condensation, all the protecting groups are removed by the above-mentioned method to obtain a desired crude protein (crude peptide).
- the crude protein (crude peptide) is purified by using various known purification means, and the main fraction is freeze-dried to obtain an amide of the desired protein (peptide).
- the ester form of the protein (peptide) can be obtained, for example, by condensing the ⁇ -hydroxyl group of the carboxy-terminal amino acid with a desired alcohol to form an amino acid ester, and then in the same manner as in the case of the amide form of the protein (peptide). Can be done.
- the partial peptide of the present invention or a salt thereof can also be produced by cleaving the protein of the present invention or a salt thereof with an appropriate peptidase.
- the protein (peptide) of the present invention is obtained by culturing a transformant containing a polynucleotide encoding the protein of the present invention or a partial peptide thereof, and transforming the protein (peptide) of the present invention from the resulting culture. It can also be produced by separation and purification.
- the polynucleotide encoding the protein of the present invention or a partial peptide thereof may be DNA or RNA, or may be a DNA / RNA chimera. Preferably, DNA is used. Further, the polynucleotide may be double-stranded or single-stranded.
- a double-stranded DNA it may be a double-stranded DNA, a double-stranded RNA or a hybrid of DNA: RNA.
- a single strand it may be a sense strand (ie, a coding strand) or an antisense strand (ie, a non-coding strand).
- Examples of the DNA encoding the protein of the present invention or a partial peptide thereof include mammals (for example, humans, pests, monkeys, pumas, bushes, sheep, goats, dogs, cats, guinea pigs, rats, Mouse, rabbit, hamster, etc.) genomic DNA, all cells of the mammal [eg, hepatocytes, spleen cells, nerve cells, Darya cells, Teng i3 cells, bone marrow cells, mesangial cells, Langerhans cells, epidermal cells, Epithelial cells, goblet cells, endothelial cells, smooth muscle cells, fibroblasts, fibroblasts, muscle cells, fat cells, immune cells (e.g., macrophages, T cells, B cells, Natural killer cells, mast cells, neutrophils, basophils, eosinophils, monocytes), megakaryocytes, synovial cells, chondrocytes, bone cells, osteoblasts, osteoclasts, breast cells, liver
- the genomic DNA and cDNA encoding the protein or its partial peptide of the present invention are obtained by using the genomic DNA fraction and the total RNA or mRNA fraction prepared from the above-described cells and tissues as type III, respectively. It can also be directly amplified by Reaction (hereinafter, abbreviated as “PCR method”) and Reverse Transcriptase-PCR (hereinafter, abbreviated as “RT-PCR method”). Alternatively, the genomic DNA and cDNA encoding the protein of the present invention or a partial peptide thereof can be obtained by inserting the genomic DNA prepared from the cells and tissues described above and the entire RNA or mRNA fragment into an appropriate vector. Each of the prepared genomic DNA library and cDNA library can be cloned by colony or plaque hybridization or PCR.
- the vector used in the library may be any of bacteriophage, plasmid, cosmid, phagemid and the like.
- Examples of the DNA encoding the protein of the present invention include a DNA containing the base sequence represented by SEQ ID NO: 1 or a base sequence that hybridizes with the base sequence under high stringent conditions; DNA encoding a protein having substantially the same activity as the protein containing the amino acid sequence represented by 2 (hereinafter sometimes abbreviated as “Sst20-14 (Long form)”); SEQ ID NO: A DNA containing the nucleotide sequence represented by 3 or a nucleotide sequence that hybridizes with the nucleotide sequence under high stringent conditions; No .: DNA encoding a protein having substantially the same activity as the protein containing the amino acid sequence represented by 4 (hereinafter sometimes abbreviated as “Sst20-14 (Short form)”); SEQ ID NO: A DNA comprising the nucleotide sequence represented by 5 or a protein comprising a nucleotide sequence that hybridizes with the nucleotide sequence under high stringency conditions and comprising the amino acid sequence represented by SEQ
- DNA encoding the protein of interest (hereinafter sometimes abbreviated as “Sstl9-15 (Long form)”); DNA containing the nucleotide sequence of SEQ ID NO: 13 or Stringent DNA encoding a protein containing a nucleotide sequence that hybridizes under the conditions and having substantially the same activity as the protein containing the amino acid sequence represented by SEQ ID NO: 14 (hereinafter, “Sstl9-15 (Short form)”).
- a DNA containing the base sequence represented by SEQ ID NO: 15 or a base sequence that hybridizes with the base sequence under high stringent conditions DNA encoding a protein having substantially the same activity as the protein having the amino acid sequence represented (hereinafter sometimes abbreviated as "Sstl3-11"); the base represented by SEQ ID NO: 17 DNA containing sequence or base sequence and DNA DNA encoding a protein containing a nucleotide sequence that hybridizes under the conditions and having substantially the same activity as the protein containing the amino acid sequence represented by SEQ ID NO: 18 (hereinafter, abbreviated as “Sst9-8”)
- the nucleotide sequence represented by each of the above SEQ ID NOs (SEQ ID NOs: 1, 3, 5, 7, 9, 11, 11, 13, 15, 17, 19, or 21) and highly stringent conditions
- the DNA that can be hybridized with the above base sequence has a homology of about 50% or more, preferably about 60% or more, more preferably about 70% or more, particularly preferably about 80% or more, and most preferably about 90% or more with the nucleotide sequence.
- DNA containing a nucleotide sequence having a property is used.
- NCBI BLAST National Center for Biotechnology Information Basic Local Alignment Search Tool
- the above-mentioned algorithm for calculating the homology of the amino acid sequence is preferably exemplified as well.
- Hybridization is carried out by a method known per se or a method analogous thereto, such as a method described in Molecular Cloning, 2nd edition (J. Sambrook et al., Cold Spring Harbor Lab. Press, 1989). Can be performed in accordance with Also, using a commercially available library, Hybridization can be performed according to the method described in the attached instruction manual. Hybridization can be performed preferably under high stringent conditions.
- High stringency conditions include, for example, a sodium salt concentration of about 19 to about 40 mM, preferably about 19 to about 20 mM, and a temperature of about 50 to about 70 ° C, preferably about 60 to about Conditions at 65 ° C., etc.
- the sodium salt concentration is about 19 mM and the temperature is about 65 ° C.
- the salt concentration of the hybridization solution, the temperature of the hybridization reaction, the probe concentration, the length of the probe, the number of mismatches, the time of the hybridization reaction, the salt concentration of the washing solution, the washing temperature, etc. Can be easily adjusted to a desired stringency by appropriately changing.
- the DNA encoding the protein of the present invention is preferably a DNA encoding the mouse SST20-14 (Long form) protein having the nucleotide sequence represented by SEQ ID NO: 1, and the nucleotide represented by SEQ ID NO: 3 DNA encoding the mouse SST20-14 (Short form) protein having the sequence, DNA encoding the mouse SST22-22 (Long form) protein having the nucleotide sequence represented by SEQ ID NO: 5, SEQ ID NO: DNA encoding the mouse SST22-22 (Short form) protein having the nucleotide sequence represented by 7, DNA encoding the mouse SST8-5 protein having the nucleotide sequence represented by SEQ ID NO: 9, SEQ ID NO: : DNA encoding the mouse SST19-15 (Long form) protein having the nucleotide sequence represented by 11, and mouse SST19-15 (Short form) protein having the nucleotide sequence represented by SEQ ID NO: 13 DNA to encode, having a base sequence represented by SEQ ID NO: 15 A
- Escherichia coli Topi 0 / pCR4-TOPO SST20-1 1 ong form
- Escherichia coli Topi 0 / pCR4-TOPO SST20-14 short form
- Topl0 / pCR4-T0P0 (SST22-221ong form), (4) Escherichia coli To lO / pCR4-TOPO (SST22-22short form), (5) Escherichia coli Topl0 / pCR4-T0P0 (SST8-5), (6) Escherichia coli Topi 0 / pCR4-T0P0 (SST19-151 long form), (7) Escherichia coli To i 0 / pCR4-TOPO (SST19-15 short form), (8)
- Escherichia coli To i 0 / pCR4-TOPO SST13-11> (9) Escherichia coli ToplO / pENTR / D-T0PO (SST9-8), (10) Escherichia coli TolO / pCR4-T0P0 (SST2 to 3) and (11) Escherichia coli ToplO / pCR4-TOPO (SST20-6)] are FERM BP-8406, FERM BP-8407, FERM BP-8408, FERM BP-8409, FERM BP-8402, FERM BP-8404, and FERM, respectively.
- a signal sequence strap (SST) method As a simple method for cloning a nucleic acid encoding a secretory or membrane protein such as the protein of the present invention, a signal sequence strap (SST) method is known. This method basically creates a cDNA library derived from the target tissue and 5 'of the DNA encoding a protein that enables cell selection only when secreted or transferred to the cell membrane. Using a fusion protein expression vector integrated on the side, secretion or translocation to the cell membrane is used as an index to select cDNA encoding a secretory or membrane protein.
- SST signal sequence strap
- a yeast expression plasmid in which a target cDNA library is fused to the 5 'side of a mutant invertase gene with a signal sequence deletion is introduced into a yeast having a mutant invertase that cannot assimilate sucrose, and sucrose is used as a carbon source.
- a method for selecting a yeast having a signal deficient mutant 5 '5' The mammalian expression vector obtained by fusing the DNA library is introduced into appropriate mammalian cells, and separated by immunostaining using an anti-CD25 antibody.
- cDNA encoding a part of secreted or membrane protein can be isolated and subcloned into an appropriate cloning vector.
- the nucleotide sequence of the cDNA thus obtained can be determined using a method known per se (such as the Maxam-Gilbert method, the dideoxy-one-minute method).
- two types of synthetic DNA primers having the partial nucleotide sequence of the above-identified and sequenced cDNA identified above and an appropriate adapter primer are used.
- the 5'- and 3'-RACE reactions are performed using the mRNA derived from the target tissue as type II, and the amplified fragments obtained are ligated using restriction enzymes and ligase to form a full-length cDNA.
- a DNA containing part or all of the above-sequenced cDNA as a probe and screening again by hybridization from the library to obtain a full-length cDNA examples include, but are not limited to, methods.
- any adapter sequence (for example, subcloning In this case, a sequence containing a restriction enzyme recognition site for signaling) with oligo dT added to the 3 ′ end may be preferably used.
- 5′-RACE when using the intrinsic terminal transferase activity of reverse transcriptase, several dCs are mainly added, and therefore an adapter primer having dG added to the 3 ′ end can be preferably used.
- the hybridization can be carried out by a method known per se or a method similar thereto, for example, Molecular Cloning, 2nd edition (J. Sambrook et al., Cold Spring Harbor Lab. Press, 1989).
- hybridization can be performed according to the method described in the attached instruction manual.
- the base sequence of the full-length cDNA thus obtained can be determined by a method known per se (Maxam's Gilbert method, dideoxy termination method, etc.) in the same manner as the partial sequence.
- DNA encoding the full-length mouse SST20-14 (Short form) protein (mSst20-14 (Short form)) is obtained from, for example, a cDNA library derived from a mouse white adipose tissue loaded with a high fat diet.
- the nucleotide sequence of the nucleic acid (mSst20-14 (partial)) obtained using the SST method and cloned into Escherichia coli TolO / pENTR / D-TOPO (20-14)
- a DNA encoding the full-length mouse SST22-22 (Short form) protein (mSst22-22 (Short form)) having a sequence is, for example, a cDNA library derived from a mouse white adipose tissue loaded with a high fat diet. Nucleotide sequence of a nucleic acid (mSst 22-22 (partial)) obtained from E.
- DNA encoding the full-length mouse SST8-5 protein (mSst8-5) having the nucleotide sequence represented by SEQ ID NO: 9 can be obtained, for example, from a cDNA library derived from a mouse white adipose tissue loaded with a high fat diet.
- the nucleotide sequence of the nucleic acid (mSst8-5 (partial)) (SEQ ID NO: 25) obtained by using the SST method and cloned into Escherichia coli ToplO / pENTR / D-TOPO (8-5) was obtained. It can be obtained by 5'- and 3'-RACE reactions using a primer designed based on the primer and an adapter primer.
- DNA (mSstl3-ll) encoding the full-length mouse SST13-11 protein having the nucleotide sequence represented by SEQ ID NO: 15 is, for example, a cDNA library derived from a mouse white adipose tissue loaded with a high fat diet.
- nucleic acid (mSstl3-ll (partial)) obtained from the E. coli Escherichia coli ToplO / pENTR / D-TOPO (13-11) strain using the SST method SEQ ID NO: It can be obtained by 5'- and 3'-RACE reaction using a primer designed based on 27) and an adapter primer.
- DNA (mSst9-8) encoding the full-length mouse SST9-8 protein having the nucleotide sequence represented by SEQ ID NO: 17 is, for example, a cDNA library derived from mouse white adipose tissue loaded with a high fat diet. From the rally using the SST method described above. And a primer designed based on the nucleotide sequence (SEQ ID NO: 28) of nucleic acid 0nSst9-8 (partial) cloned into Escherichia coli TolO / pENTR / D-TOPO (9-8) strain. It can be obtained by 5'- and 3, -RACE reactions using adapter primers.
- DNA (mSst21-3) encoding the full-length mouse SST21-3 protein having the nucleotide sequence represented by SEQ ID NO: 19 is, for example, cDNA derived from mouse white adipose tissue loaded with a high fat diet.
- DNA (mSst20-6) encoding the full-length mouse SST20-6 protein having the nucleotide sequence represented by SEQ ID NO: 21 is, for example, a cDNA library derived from mouse white adipose tissue loaded with a high fat diet.
- Base sequence of a nucleic acid (mSst20-6 (partial)) obtained from the rally using the above SST method and cloned into Escherichia coli ToplO / pENTR / D-TOPO (20-6) strain (SEQ ID NO: It can be obtained by 5'- and 3'-RACE reaction using a primer designed based on 30) and an adapter primer.
- Escherichia coli ToplO / pENTR / D-TOPO (20-14), Escherichia coli ToplO / pENTR / D-TOPO (22-22), Escherichia coli TolO / pENTR / D-T0P0 (8-5) , Escherichia coli ToplO / pENTR / D-TOPO (19-15) strain,
- Escherichia coli TolO / pENTR / D-TOPO 13-11) strain
- Escherichia coli ToplO / pENTR / D-TOPO 9-8) strain
- Escherichia coli TolO / pENTR / D-TOPO (21-3) strain
- Escherichia coli ToplO / pENTR / D-TOPO (20-6) strains are FERM BP-8104, FERM BP-8109, FERM BP-8110, FERM BP-8108, FERM BP-8107, FERM BP-8105, FERM BP, respectively.
- the DNA encoding the partial peptide of the present invention is a DNA of the amino acid sequence represented by each of the above SEQ ID NOs (SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, or 22). Any nucleotide may be used as long as it contains a nucleotide sequence encoding a peptide having the same or substantially the same amino acid sequence as the amino acid sequence.
- the DNA encoding the partial peptide of the present invention includes, for example, (1) a partial nucleotide sequence of the nucleotide sequence represented by each of the above SEQ ID NOs or (2) a nucleotide represented by each of the above SEQ ID NOs: It has a base sequence that hybridizes under high stringent conditions to DNA having a sequence, and has substantially the same activity as the above-mentioned protein of the present invention (eg, binding activity of receptor (or ligand), signaling activity, etc.) ) Which encodes a peptide having
- Examples of the DNA that can hybridize with the DNA having the nucleotide sequence represented by each of the above-mentioned SEQ ID NOs under high stringent conditions include, for example, about 60% or more, preferably about 70% or more, more preferably Examples include a DNA containing a nucleotide sequence having an identity of about 80% or more, most preferably about 90% or more.
- High stringency conditions include the same conditions as above.
- the nucleotide sequence of the cloned DNA encoding the protein of the present invention or its partial peptide can be obtained from known kits such as Mutan TM -super Express Km (Takara Shuzo), Mutan TM -K (Takara Shuzo) )), ODA-LA PCR,
- the conversion can be carried out according to a method known per se, such as the gapped duplex method and the Kunkel method, or a method analogous thereto.
- the cloned DNA can be used as it is depending on the purpose, or after digesting with a restriction enzyme or adding a linker, if desired.
- the DNA may have ATG at the 5 'end as a translation initiation codon, and may have TAA, TGA or TAG at the 3' end as a translation stop codon. These translation initiation codon and translation termination codon can be added using a suitable synthetic DNA adapter.
- DNA containing the above-described protein of the present invention or a partial peptide thereof is included.
- the protein (peptide) of the present invention can be produced.
- An expression vector containing a DNA encoding the protein of the present invention or a partial peptide thereof can be obtained, for example, by cutting out a DNA fragment of interest from the DNA encoding the protein and placing the DNA fragment downstream of a promoter in an appropriate expression vector. It can be manufactured by connecting to
- Escherichia coli-derived plasmids eg, pBR322, pBR325, pUC12, pUC13); Bacillus subtilis-derived plasmids (eg, pUB110, pTP5, pC194); yeast Derived plasmids (eg, pSH19, pSH15); insect cell expression plasmids (eg, pFast—Bac); animal cell expression plasmids (eg, PAI-11, pXTl, pRcZCMV, pRc / RSV, bacteriophage such as ⁇ phage; insect virus vectors such as baculovirus (eg, BmNPV, AcNPV); animal virus vectors such as retrovirus, vaccinia virus, and adenovirus.
- Bacillus subtilis-derived plasmids eg, pUB110, pTP5, pC194
- the promoter may be any promoter as long as it is appropriate for the host used for gene expression.
- SR promoter SV40 promoter, LTR promoter, CMV (cytomegalovirus) promoter, RSV (Rous sarcoma virus) promoter, MoMuLV (molo mouse) Leukemia virus) LTR, HS V-TK (simple virus virus thymidine kinase) Promoter etc.
- CMV promoter, SRa promoter and the like are preferable.
- trp promoter Isseki one 1 ac promoter - coater, re cA promoter one, eh P L promoter, lpp promoter evening one, such as T 7 promoter are preferred.
- the SPO1 promoter, SP02 promoter, penP promoter and the like are preferable.
- PH ⁇ 5 promoter PH ⁇ 5 promoter
- PGK promoter G
- G An AP promoter, an ADH promoter and the like are preferred.
- a polyhedrin promoter When the host is an insect cell, a polyhedrin promoter, a P10 promoter and the like are preferred.
- an expression vector in addition to the above, those containing an enhancer, a splicing signal, a polyA addition signal, a selection marker, an SV40 replication origin (hereinafter sometimes abbreviated as SV40 ori) and the like, if desired, etc. Can be used.
- the selection marker include dihydrofolate reductase gene (hereinafter sometimes abbreviated as dhfr, Mesotorekise Ichito (M TX) resistance), the ampicillin resistance gene (hereinafter sometimes abbreviated as # 038 r), neomycin Resistance gene (hereinafter sometimes abbreviated as neo 1 , G418 resistance), etc.
- dh fr gene-deficient Chinese Hamster cells are used and the dh fr gene is used as a selection marker, thymidine is included.
- the target gene can also be selected depending on the medium used.
- a base sequence (signal codon) encoding a signal sequence suitable for the host may be added to the 5 ′ end of the DNA encoding the protein of the present invention or a partial peptide thereof (or a native signal codon). With).
- the host when the host is a bacterium belonging to the genus Escherichia, a PhoA * signal sequence, an OmpA signal sequence, and the like:
- the host When the host is a bacterium belonging to the genus Bacillus, an ⁇ -amylase signal sequence, a subtilisin signal sequence, and the like;
- yeast In the case of yeast, MF-signal sequence, SUC2-signal sequence, etc .
- insulin-signal sequence, hyphen-feron, signal sequence, antibody molecule, signal sequence, etc. are used, respectively. It is possible.
- Escherichia bacteria for example, Escherichia bacteria, Bacillus bacteria, yeast, insect cells, insects, animal cells and the like are used.
- Escherichia examples include, for example, Escherichia coli K12 ⁇ DH1 [Procedures of the National Academy of Sciences, Proc. Natl. Acad. Sci. USA), 60, 160 (1968)], Escherichia coli JM103 [Nucleic Acids Research, Vol. 9, 309 (1981)), Escherichia Kori J 221 [Journal of Molecular Biology, 120, 517 (1978)] ], Escherichia coli 101 (Journal of Molecular Molecular Biology, 41, 459 (1969)), Escherichia coli C600 (Genetics, 39, 440 (1954)), etc. Is used.
- Bacillus species include, for example, Bacillus subtilis (Bacillus subtilis) MI 114 (Gene, 24, 255 (1983)), Bacillus subtilis 207-21 (Journal of Bob Biochemistry).
- yeast examples include, for example, Saccharomyces cerevisiae AH22, AH22R—, NA87-11A, DKD-5D, 20B-12 Schizosaccharomyces pombe NCYC 1913, NCYC2036, Pichia 'Pastris
- Insect cells include, for example, when the virus is Ac NPV, a cell line derived from night larvae of moth larvae (Spodoptera frugiperda cell; Sf cell), MG1 cells derived from the midgut of Trichoplusia ni, and High Five derived from eggs of Trichoplusia ni TM cells, cells derived from Mamestra brass icae, cells derived from Estigmena acrea, and the like.
- the virus is BmNPV
- the insect cells include silkworm-derived cell lines.
- Sf cell (Bombyx mori N cells; BmN cells).
- Sf9 cell ATCC CRL1711
- Sf21 cell (Vaughn, 'JL et al., In Vivo, 13, 213-217, (1977)) and the like. Is used.
- insects for example, silkworm larvae are used [Maeda et al., Nature, Vol. 315, 592 (1985)].
- animal cells examples include monkey COS-7 cells, monkey Vero cells, Chinese hamster cells CHO (hereinafter abbreviated as CHO cells), dh fr Gene-deficient Chinese hamster cells CHO (hereinafter abbreviated as CHO (dhfr-) cells), mouse L cells, mouse AtT-20 cells, mouse myeoma cells, rat GH3 cells, human FL cells, etc. are used. .
- Transformation can be performed according to a known method depending on the type of host.
- the genus Escherichia is described in, for example, Proc. Natl. Acad. Sci. USA, Proc. Natl. Acad. Sci. (1972) and Gene ; 17 ; 107 (1982).
- Bacillus sp. Can be transformed, for example, according to the method described in Molecular & General Genetics, 168, 11 (1979).
- Yeasts are, for example, Methods in Enzymology
- Insect cells and insects are, for example, biotechnology
- Animal cells are transformed according to the method described in, for example, Cell Engineering Separate Volume 8, New Cell Engineering Experimental Protocol, 263-267 (1995) (published by Shujunsha), Virology, 52, 456 (1973).
- the culturing of the transformant can be carried out according to a known method depending on the type of the host.
- a liquid medium is preferable as the medium used for the culture.
- the medium contains the carbon source, nitrogen source, inorganic substances, etc. necessary for the growth of the transformant.
- a carbon source for example, glucose, dextrin, soluble starch, sucrose, etc .
- a nitrogen source for example, ammonium salts, nitrates, corn steep liquor, peptone, casein, meat extract, Inorganic or organic substances such as soybean meal and potato extract
- examples of the inorganic substances include calcium chloride, sodium dihydrogen phosphate, and magnesium chloride.
- the medium may be supplemented with yeast extract, vitamins, growth promoting factors and the like.
- the pH of the medium is preferably from about 5 to about 8.
- a medium for culturing a transformant whose host is Escherichia sp. For example, an M9 medium containing glucose and casamino acid [Miller, Ja-Nar-Ov-Esperimen 'in' Molecular ⁇ Genetics (Journal of Experiments in Molecular Genetics), 431-433, Cold Spring Harbor Laboratory, New York 1972] are preferred.
- an agent such as 3-indolylacrylic acid may be added to the medium to make the promoter work efficiently.
- Culture of a transformant whose host is a bacterium belonging to the genus Escherichia is usually performed at about 15 to about 43 ° C. for about 3 to about 24 hours. If necessary, ventilation or stirring may be performed.
- Culture of the transformant whose host is a bacterium of the genus Bacillus is usually performed at about 30 to about 40 ° C. for about 6 to about 24 hours. If necessary, ventilation or stirring may be performed.
- a medium for culturing a transformant in which the host is yeast for example, a minimal medium (Burkholder) minimum medium [Bostian, KL, et al., Proceedings of the National Academy of Sciences, Inc. Proc. Natl. Acad. Sci. USA, 77, 4505 (1980)] and SD medium containing 0.5% casamino acid CBitter, GA, Proc. Prob. Natl. Acad. Sci. USA, 81, 5 330 (1 984)].
- the pH of the medium is preferably from about 5 to about 8.
- the cultivation is usually performed at about 20 to about 35, for about 24 to about 72 hours. Ventilation or stirring may be performed as necessary.
- a medium for culturing an insect cell or a transformant whose host is an insect for example, 10% inactivated in Grace's Insect Medium [Grace, T., Nature, 195, 788 (1962)] Those to which additives such as serum are appropriately added are used.
- the pH of the medium is preferably from about 6.2 to about 6.4. Culturing is usually about 27, and is performed for about 3 to about 5 days. Ventilation or stirring may be performed as necessary.
- the pH of the medium is preferably from about 6 to about 8.
- the cultivation is usually about 30 to about 40, and is performed for about 15 to about 60 hours. Aeration and stirring may be performed as necessary.
- the protein (peptide) of the present invention can be produced inside or outside the cells of the transformant.
- the protein (peptide) of the present invention can be separated and purified from a culture obtained by culturing the transformant according to a method known per se.
- the cells or cells collected from the culture by a known method are suspended in an appropriate buffer, and then subjected to ultrasound, lysozyme and After the cells or cells are destroyed by freeze-thawing or the like, a method of obtaining a crude extract of soluble protein by centrifugation or filtration is appropriately used.
- the buffer may contain a protein denaturant such as urea or guanidine hydrochloride, or a surfactant such as Triton X-100 TM .
- the protein (peptide) of the present invention contained in the soluble fraction, membrane fraction or culture supernatant thus obtained can be isolated and purified according to a method known per se.
- Such methods include methods that utilize solubility such as salting out and solvent precipitation; methods that mainly use differences in molecular weight, such as dialysis, ultrafiltration, gel filtration, and SDS-polyacrylamide gel electrophoresis. Method; method using difference in charge such as ion exchange chromatography; method using specific affinity such as affinity chromatography; use difference in hydrophobicity such as reverse phase high performance liquid chromatography A method utilizing a difference between isoelectric points, such as isoelectric focusing, and the like. These methods can be appropriately combined.
- the free form can be converted to a salt by a method known per se or a method analogous thereto, and when the protein or peptide is obtained as a salt, The salt can be converted into a free form or another salt by a method known per se or a method analogous thereto.
- the protein (peptide) of the present invention produced by the transformant may be arbitrarily modified or the polypeptide may be partially removed before or after purification by the action of an appropriate protein-modifying enzyme. You can also.
- the protein-modifying enzyme for example, trypsin, chymotrypsin, arginyl endopeptidase, protein kinase, glycosidase and the like are used.
- the protein (peptide) of the present invention is a non-human protein consisting of an RNA corresponding to the DNA encoding the protein of the present invention or a partial peptide thereof as a type II, such as a heron reticulocyte lysate, a wheat germ lysate, and an Escherichia coli lysate.
- a DNA encoding the protein of the present invention or a partial peptide thereof can also be synthesized in type III using a cell-free transcription Z translation system containing RNA polymerase.
- the protein of the present invention (ie, identical or substantially identical to the amino acid sequence represented by SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 16, 18, 20, or 22)
- the resulting nucleic acid can be said to be “antisense” to the target nucleic acid, while a nucleic acid containing a base sequence having homology to the target region of the target nucleic acid is referred to as a “sense” to the target nucleic acid.
- “having homology” or “complementary” refers to about 70% or more, preferably about 80% or more, more preferably about 90% or more between base sequences.
- the nucleic acid has a nucleotide sequence complementary to the nucleotide sequence encoding the protein of the present invention or a part thereof (hereinafter, referred to as “95% or more identity or complementarity”).
- the “antisense nucleic acid of the present invention” may be designed and synthesized based on the cloned or determined base sequence information of the nucleic acid encoding the protein of the present invention.
- the antisense nucleic acid of the present invention can hybridize with the RNA transcribed from the gene encoding the protein of the present invention. , It is possible to inhibit the synthesis of mR NA (processing) or function (translation into protein).
- the target region of the antisense nucleic acid of the present invention is a hybrid where the antisense nucleic acid is hybridized.
- the length is not particularly limited as long as the translation of the protein of the present invention is inhibited as a result.
- the entire sequence of the mRNA encoding the protein may be a partial sequence.
- the short one may be about 15 bases, and the long one may be the entire sequence of mRNA or early transcript. Considering the ease of synthesis and antigenicity, oligonucleotides consisting of about 15 to about 30 bases are preferred, but not limited thereto.
- the 5'-end hairpin loop, 5'-end 6—base pair 'repeat, 5'-end untranslated region, 5'-end untranslated region, polypeptide translation initiation codon, and protein coding region of the nucleic acid encoding the protein of the present invention can be selected as target regions, but any region in the gene encoding the protein of the present invention can be selected. Can be selected as target. For example, it is also preferable to use the intron portion of the gene as a target region.
- the antisense nucleic acid of the present invention not only hybridizes with mRNA or the initial transcript encoding the protein of the present invention to inhibit translation into the protein, but also encodes the protein of the present invention which is a double-stranded DNA. May form a triplex (tripleplex) by binding to a gene that causes RNA transcription.
- Antisense nucleic acids may be deoxysilipnucleotides containing 2-dexoxy_D-reports, ribonucleotides containing D-reports, or other types of nucleotides that are N-glycosides of primines or pyrimidine bases. Or other polymers having a non-nucleotide backbone (eg, commercially available protein nucleic acids and synthetic sequence-specific nucleic acid polymers) or other polymers containing special bonds (provided that the polymer is in DNA or RNA) Pairing of bases (including nucleotides having a configuration that allows base attachment) as described in (1).
- RNA hybrids can be double-stranded DNA, single-stranded DNA, double-stranded RNA, single-stranded RNA, and also DNA: RNA hybrids, and can also be unmodified polynucleotides (or unmodified oligonucleotides).
- Natural nucleotides substituted by analogs modified intramolecular nucleotides, such as those with uncharged bonds (eg, methylphosphonate, phosphotriester, phosphoramidate, olebamate, etc.), charged bonds Or those having sulfur-containing bonds (eg, phosphorothioate, phosphorodithioate, etc.), such as proteins (nucleases, nucleases, inhibitors, toxins, antibodies, signal peptides, poly-L-lysine, etc.) , Sugars (eg, monosaccharides, etc.) with side-chain groups, in-current compounds (eg, acridine, psoralen, etc.), chelating compounds (eg, metals, radioactive metals) , Boron, oxidizing metals, etc.) Those containing alkylating agents, those with modified linkages (e.g.
- nucleic acid may be used.
- the “nucleoside”, “nucleotide” and “nucleic acid” may include not only those containing purine and pyrimidine bases but also those having other modified heterocyclic bases. Such modifications may include methylated purines and pyrimidines, acylated purines and pyrimidines, or other heterocycles. Modified nucleotides and modified nucleotides may also be modified at the sugar moiety, e.g., where one or more hydroxyl groups have been replaced with halogens, aliphatic groups, etc., or functionalities such as ethers, amines, etc. It may be converted to a group.
- Antisense nucleic acids are RNA, DNA, or modified nucleic acids (RNA, DNA).
- modified nucleic acid include, but are not limited to, sulfur derivatives of nucleic acids, thiophosphate derivatives, and polynucleoside amides, which are resistant to degradation of oligonucleoside amides.
- Antisense nucleic acids can be preferably designed according to the following policy. That is, to make the antisense nucleic acid more stable in the cell, to make the antisense nucleic acid more cell permeable, to have a greater affinity for the target sense strand, and to be more toxic if it is toxic. Make sense nucleic acids less toxic. Many such modifications are known in the art, for example, J. Kawakami et al., Pharm Tech Japan, Vol. 8, pp. 247, 1992; Vol. 8, pp. 395, 1992; disclosed in ST Crooke et al. Ed., Antisense Research and Applications, CRC Press, 1993.
- Antisense nucleic acids can contain altered or modified sugars, bases, or linkages, can be provided in special forms such as ribosomes, microspheres, applied by gene therapy, or added forms.
- the addition forms include polycations such as polylysine, which acts to neutralize the charge of the phosphate skeleton, and lipids, which enhance the interaction with cell membranes and increase the uptake of nucleic acids ( For example, crude water-based substances such as phospholipids and cholesterol are exemplified.
- Preferred lipids for addition include cholesterol and its derivatives (eg, cholesteryl chromate formate, cholic acid, etc.).
- nucleic acid can be attached via a base, sugar, or intramolecular nucleoside bond.
- Other groups include cap groups that are specifically located at the 3 'or 5' end of nucleic acids to prevent degradation by nucleases such as exonucleases and RNases.
- capping groups include, but are not limited to, hydroxyl-protecting groups known in the art, such as dalicol such as polyethylene dalicol and tetraethylene glycol.
- a ribozyme capable of specifically cleaving mRNA or an early transcript encoding the protein of the present invention inside the coding region (including an intron portion in the case of the initial transcript) is also included in the antisense nucleic acid of the present invention.
- the term "ribozyme” refers to RNA having an enzymatic activity for cleaving a nucleic acid. Recently, it has been revealed that oligo DNA having the nucleotide sequence of the enzyme active site also has a nucleic acid-cleaving activity. Therefore, in the present specification, the term is used as a concept including DNA as long as it has sequence-specific nucleic acid cleavage activity.
- the most versatile liposomes include self-splicing RNAs found in infectious RNAs such as Viroid and Willsoid, and hammerhead and hairpin types are known.
- Hammerhead type is about 40 bases
- the target mRNA can be expressed by decomposing the target mRNA by making several bases (about 10 bases in total) at both ends adjacent to the hammerhead structure into a sequence that is complementary to the desired cleavage site of the mRNA.
- This type of ribozyme has the additional advantage that it does not attack genomic DNA, since it uses only RNA as a substrate.
- the target sequence can be determined by using a hybrid liposome linked to an RNA motif derived from a viral nucleic acid that can specifically bind to an RNA helicase. Acad. Sci. USA, 98 (10): 5572-5577 (2001)].
- the ribozyme is used in the form of an expression vector containing the DNA encoding the ribozyme, a hybrid in which a tRNA-modified sequence is further ligated to promote the transfer of the transcript to the cytoplasm. It can also be used as a driposium [Nucleic Acids Res., 29 (13): 2780-2788 (2001)].
- RNA interference RNA interference
- the antisense oligonucleotide and ribozyme of the present invention determine the target region of mRNA or early transcript based on the cDNA or genomic DNA sequence information encoding the protein of the present invention, and are commercially available DNAZRNA automated. It can be prepared by synthesizing a complementary sequence using a synthesizer (Applied Biosystems, Beckman, etc.). For siRNA having RNAi activity, the sense strand and the antisense strand are each synthesized using a DNAZRNA automatic synthesizer, denatured in a suitable annealing buffer, for example, at about 90 to about 95, for about 1 minute, and then denatured.
- About 30 to about 70 and about 1 to about 8 It can be prepared by annealing for a time. It is also possible to prepare longer double-stranded polynucleotides by synthesizing complementary oligonucleotide strands so that they alternate with each other, annealing them, and ligating them with ligase. it can.
- the gene expression-inhibiting activity of the antisense nucleic acid of the present invention may be determined by using a transformant containing the nucleic acid encoding the protein of the present invention, a gene expression system encoding the protein of the present invention in vivo or in vitro, or a gene expression system encoding the same. It can be examined using a translation system of the protein of the invention in vivo or in vitro.
- the nucleic acid can be applied to cells by various methods known per se.
- the present invention also provides an antibody against the protein (peptide) of the present invention.
- the antibody may be a monoclonal antibody or a polyclonal antibody as long as it has a specific affinity for the protein (peptide) of the present invention.
- An antibody against the protein (peptide) of the present invention can be produced by using the protein (peptide) as an antigen according to a method known per se for producing an antibody or antiserum.
- the protein (peptide) of the present invention is administered to a mammal at a site where the antibody can be produced by administration, itself or together with a carrier and a diluent.
- Complete Freund's adjuvant or incomplete Freund's adjuvant may be administered to enhance the antibody-producing ability upon administration. Administration is usually performed once every 2 to 6 weeks, for a total of about 2 to 10 times. Examples of mammals to be used include monkeys, ⁇ herons, dogs, guinea pigs, mice, rats, sheep, goats, and mice and rats are preferably used.
- a mammal immunized with the antigen for example, a mouse with an antibody titer is selected from a mouse, and the spleen or lymph node is collected 2 to 5 days after the final immunization.
- a monoclonal antibody-producing hybridoma By fusing the antibody-producing cells contained with the myeloma cells, a monoclonal antibody-producing hybridoma can be prepared.
- the measurement of the antibody titer in the antiserum is performed, for example, by labeling described below. After reacting SS169s with antiserum, the activity can be measured by measuring the activity of the labeling agent bound to the antibody.
- the fusion operation can be carried out according to a known method, for example, the method of Kera and Milstein [Nature (Nature, 256, 495, 1975)].
- Glycol (PEG), Sendai virus and the like can be mentioned, but PEG is preferably used.
- myeloma cells examples include NS-1, P3U1, and 3 to 20, and P3U1 is preferably used.
- the preferred ratio between the number of antibody-producing cells (spleen cells) and the number of myeloma cells used is about 1: 1 to 20: 1, and the concentration of PEG (preferably PEG1000 to PEG6000) is about 10 to 80%.
- the cell fusion can be carried out efficiently by incubating at about 20 to 40, preferably about 30 to 37 for about 1 to 10 minutes.
- a hybridoma culture supernatant is added to a solid phase (eg, microplate) on which an antigen such as a protein is adsorbed directly or together with a carrier.
- an anti-immunoglobulin antibody labeled with a radioactive substance or an enzyme if the cell used for cell fusion is a mouse, an anti-mouse immunoglobulin antibody is used) or protein A, is added, and the monoclonal antibody bound to the solid phase is added.
- Detection method Hybridoma culture supernatant is added to the solid phase to which anti-immunoglobulin antibody or protein A is adsorbed, and proteins etc.
- the selection of the monoclonal antibody can be carried out according to a method known per se or a method analogous thereto, but is usually carried out in a medium for animal cells to which HAT (hypoxanthine, aminopterin, thymidine) is added.
- HAT hyperxanthine, aminopterin, thymidine
- any medium can be used as long as it can grow a hybridoma.
- RPMI 1640 medium containing 1 to 20%, preferably 10 to 20% fetal bovine serum, GI ⁇ medium (Wako Pure Chemical Industries, Ltd.) or hybridoma culture containing 1 to 10% fetal bovine serum Serum-free medium (SFM-101, Nissui Pharmaceutical Co., Ltd.) or the like can be used.
- the culture temperature is Usually it is 20 to 40, preferably about 37 ° C.
- the culture time is usually 5 days to 3 weeks, preferably 1 week to 2 weeks.
- the culture can be usually performed under 5% carbon dioxide.
- the antibody titer of the hybridoma culture supernatant can be measured in the same manner as the measurement of the antibody titer in the antiserum described above.
- Monoclonal antibodies can be separated and purified in the same manner as ordinary polyclonal antibodies.
- salting out alcohol precipitation, isoelectric focusing, electrophoresis, ion exchanger ( (E.g., DEAE) adsorption / desorption method, ultracentrifugation method, gel filtration method, antigen-binding solid phase or specific antibody that only binds to the active adsorbent such as protein A or protein G and dissociates the bond to obtain the antibody Purification method].
- ion exchanger (E.g., DEAE) adsorption / desorption method
- ultracentrifugation method ultracentrifugation method
- gel filtration method antigen-binding solid phase or specific antibody that only binds to the active adsorbent such as protein A or protein G and dissociates the bond to obtain the antibody Purification method.
- the polyclonal antibody of the present invention can be produced according to a method known per se or a method analogous thereto. For example, a complex of an immunizing antigen (an antigen such as a protein) and a carrier-protein is formed, and a mammal is immunized in the same manner as in the above-described method for producing a monoclonal antibody, and the protein (peptide) of the present invention is immunized from the immunized animal. ) Can be produced by collecting the antibody-containing substance against and separating and purifying the antibody.
- the type of carrier protein and the mixing ratio between the carrier and the hapten are determined by the fact that the antibody is efficiently used for the hapten immunized by crosslinking the carrier. If possible, any material may be cross-linked at any ratio.For example, serum serum albumin, thyroglobulin, keyhole 'limpet' hemocyanin, etc. in a weight ratio of 1 hapten to 1 hapten About 0.:! A method of coupling at a rate of about 20 to 20 and preferably about 1 to 5 is used.
- condensation product is administered to a mammal at a site where antibody production is possible or together with a carrier or diluent.
- Complete Freund's adjuvant or incomplete Freund's adjuvant may be administered in order to enhance the antibody-producing ability upon administration.
- the administration can usually be performed once every about 2 to 6 weeks, for a total of about 3 to 10 times.
- the polyclonal antibody can be collected from blood, preferably ascites, etc., of a mammal immunized by the above method, preferably from blood.
- the measurement of the polyclonal antibody titer in the antiserum can be performed in the same manner as the measurement of the antibody titer in the serum described above.
- the separation and purification of the polyclonal antibody can be performed according to the same method for separation and purification of immunoglobulin as in the above-mentioned separation and purification of the monoclonal antibody.
- Expression localization eg, white adipose tissue, brown adipose tissue, liver, skeletal muscle, etc.
- high stress conditions eg, high-fat diet, fasting, re-feeding after fasting, stimulation of insulin resistance inducer
- the expression fluctuations are based on the cloned cDNA as it is or on the determined base sequence.
- Identification can be performed by performing quantitative RT-PCR using synthetic oligonucleotides as primers.
- All of the genes encoding the protein of the present invention are highly expressed in white adipose tissue loaded with a high fat diet.
- the Sst20-14 gene shows expression specific to white adipose tissue
- the Sstl9-15, Sstl3-ll, Sst9-8, and Sst23 genes are also expressed in brown adipose tissue.
- the Sst21-3 gene is also expressed in undifferentiated preadipocytes.
- the expression of the Sst20-14 gene decreases during fasting, and increases (recovers) after refasting after fasting. Further, the expression of the gene decreases in response to stimulation of an insulin resistance-inducing factor such as TNF-string. Also, due to overexpression of the gene, Differentiation of preadipocytes into mature adipocytes is suppressed.
- the expression of the Sst8-5 gene increases in response to stimulation of an insulin sensitizer.
- the expression of the Sstl3-11 gene decreases during fasting, and increases (recovers) after refasting after fasting.
- the expression of the gene increases in response to high fat and high sucrose load. Furthermore, the gene is highly expressed in obesity models.
- the expression of the Sst21-3 gene decreases during fasting, and increases (recovers) after refasting after fasting.
- the gene is highly expressed in a diabetes model.
- the expression of the Sstl9-15 gene also decreases during fasting, and increases (recovers) when fasted again.
- the expression of the gene encoding the protein of the present invention varies in response to diet or stimulation of insulin resistance regulators, or in obesity or diabetes, and in the expression of fat cells Affects differentiation.
- the protein (peptide) of the present invention a nucleic acid (including an antisense nucleic acid) encoding the protein (peptide), and an antibody against the protein (peptide) are: Determination of a compound having a specific affinity (a ligand for the protein of the present invention if it is a membrane protein, a receptor for a secretory protein if it is a secretory protein), (2) a disease associated with dysfunction of the protein of the present invention (3) Prevention and treatment of diseases associated with overexpression of the protein of the present invention, (4) Gene diagnostic agent, (5) Screening for compounds that alter the expression level of the protein of the present invention A method for preventing or treating various diseases containing a compound that alters the expression level of the protein of the present invention, (7) a method for quantifying a compound having a specific affinity for the protein of the present invention, 8) a method for screening a compound (eg, agonist, angonist, etc.) that changes the binding property between the protein of the present invention and a compound having
- prophylactic / therapeutic agents for various diseases which contain compounds (argonist, angonist gonist) that change the binding property to a compound having a specific affinity for the protein and (10) the protein (peptide of the present invention) (11) a method of screening for a compound that alters the amount of the protein of the present invention in the cell membrane or extracellular fluid; (12) a method of altering the amount of the protein of the present invention in the cell membrane or extracellular fluid.
- Prophylactic / therapeutic agents for various diseases containing a compound to be added; (13) the protein of the present invention;
- non-human transgenic animal having a DNA encoding the (peptide), (14) for producing a knockout non-human animal in which the gene encoding the protein of the present invention is inactivated, and the like.
- the protein (peptide) of the present invention is a compound having a specific affinity for the protein of the present invention or a salt thereof (receptase). Or ligand) is useful as a reagent for searching or determining.
- the present invention provides a method for determining a compound having a specific affinity for the protein of the present invention or a salt thereof, which comprises contacting the protein (peptide) of the present invention with a test compound.
- the protein of the present invention is a membrane receptor
- a known ligand eg, angiotensin, bombesin, canapinoid, cholecystokinin, glutamine, serotonin, melatonin, neuropeptide Y, opioid
- Purine vasopleucine, oxytocin, PACAP, secretin, glucagon, calcitonin, adrenomedullin, somatos, GHRH, CRF, ACTH, GRP, PTH, VIP (Vasoactive Intestinal and Restricted Polypeptide), somatosuccine , Dopamine, motilin, amylin, bradykinin, CGRP (calcito-ningene relayed peptide), leukotriene, pancreastati , Prostaglandins, thromboxanes, adenosine, adrenaline, paraffin and] 3-chemokines (eg,
- the tissue extract, cell culture supernatant, or the like is added to the receptor protein of the present invention, and fractionation is performed while measuring cell stimulating activity and the like, thereby finally obtaining a single ligand.
- the test compound may be, for example, a human or mammalian tissue extract, an intact cell, or a cell membrane fraction in the same manner as described above, in addition to the known receptor for the ligand.
- Cell culture supernatant and the like are used.
- the tissue extract, intact cells, cell membrane fraction, cell culture supernatant, and the like are added to the secreted protein of the present invention, and fractionated while measuring cell stimulating activity and the like. Etc. can be obtained.
- a method for determining a compound having a specific affinity for the protein of the present invention or a salt thereof uses the protein (peptide) of the present invention or expresses the protein (peptide) by recombination.
- the cell stimulating activity eg, arachidonic acid release, acetylcholine release, intracellular Ca. 2+ release, intracellular c AMP generation, intracellular c GMP generation, inositol phosphate production, fluctuations in cell membrane potential, intracellular protein phosphorylation, c-fos activation, pH reduction, etc.
- the secretory protein of the present invention and Compound of having stimulatory activity, or a method to determine their salts eg, arachidonic acid release, acetylcholine release, intracellular Ca).
- the cell stimulating activity eg, arachidonic acid release, acetylcholine release, intracellular Ca
- 2+ release intracellular c AMP generation, intracellular c GMP generation, inositol phosphat
- the protein (peptide) of the present invention is contacted with a test compound.
- a test compound for example, the amount of a test compound bound to the protein (peptide), cell stimulating activity, and the like are measured.
- the present invention provides
- the protein of the present invention or a protein thereof which is characterized by measuring the amount of binding of the labeled test compound to the protein (peptide) when the labeled test compound is brought into contact with the protein (peptide) of the present invention.
- a method for determining a compound having a specific affinity for a salt is characterized by measuring the amount of binding of the labeled test compound to the protein (peptide) when the labeled test compound is brought into contact with the protein (peptide) of the present invention.
- a labeled test compound is added to a cell or cell membrane fraction that produces the protein of the present invention, or an extracellular solution or cell culture supernatant (for example, in this case, a solid phase on which the antibody of the present invention is immobilized (cell culture) Immobilizing the secreted protein using a plate, etc.), and measuring the amount of the labeled test compound bound to the cells, the membrane fraction, the extracellular solution, or the cell culture supernatant.
- the labeled test compound was expressed on the cell membrane by culturing a transformant containing DNA encoding the protein of the present invention or its partial peptide, or secreted into the culture supernatant.
- a protein for example, the secretory protein (peptide) is immobilized using a solid phase (cell culture plate or the like) on which the antibody of the present invention is immobilized
- a method for determining a compound having a specific affinity for the protein or a salt thereof of the present invention which comprises measuring the amount of binding of the identified test compound to the protein or a salt thereof.
- the test compound (or a cell containing a test compound such as a membrane protein on the cell membrane) is transferred to a cell producing the membrane protein of the present invention (or a culture supernatant of a cell producing the secretory protein of the present invention).
- Cell stimulating activity eg, arachidonic acid release, acetylcholine release, intracellular Ca 2+ release, intracellular
- cAMP production e.g, arachidonic acid release, acetylcholine release, intracellular Ca 2+ release, intracellular
- a membrane protein which is a test compound when contacted cAMP production, intracellular cGMP production, inositol phosphate production, cell membrane potential fluctuation, intracellular protein phosphorylation, activation of c-fos, pH reduction, etc.
- test compound (or a cell containing a membrane protein or the like as a test compound on the cell membrane) is expressed on the cell membrane by culturing a transformant containing a DNA encoding the membrane protein of the present invention.
- the membrane of the present invention when contacted with the membrane protein (or the secretory protein secreted in the culture supernatant by culturing a transformant containing the DNA encoding the secretory protein of the present invention).
- ⁇ white matter (or test compound in a membrane protein, etc.) mediated cell stimulating activity e.g., Arakidon acid release, acetylcholine release, intracellular C a 2 + release, intracellular C AM P production, intracellular c GM P product, inositol Phosphate production, cell membrane potential fluctuations, phosphorylation of intracellular proteins, activation of c-fos, activity to promote or suppress pH reduction, etc.
- test compound binds to the protein (peptide) of the present invention.
- the protein (peptide) of the present invention used in the method for determining a ligand (or receptor) may be any of the above-described protein of the present invention or a partial peptide thereof or a salt thereof.
- the recombinant protein of the present invention and the like, which are expressed in a large amount by using it, are suitable.
- the above-mentioned expression method is used for producing the recombinant protein of the present invention, but it is preferable to express the DNA encoding the protein of the present invention in mammalian cells or insect cells.
- cDNA is usually used, but is not necessarily limited to this.
- a gene fragment or a synthetic DNA may be used.
- the DNA fragment should be a promoter derived from SV40. Overnight, retrovirus promoter, meta-oral thionein promoter, human heat shock promoter, cytomegalovirus promoter, evening, SRO!
- the protein (peptide) of the present invention is obtained by purifying the protein of the present invention by a method known per se.
- the cells When cells producing the protein (peptide) of the present invention are used in the method for determining a ligand of the present invention, the cells may be immobilized with daltaraldehyde, formalin, or the like.
- the immobilization method can be performed according to a method known per se.
- the cell containing the protein (peptide) of the present invention refers to a host cell expressing the protein (peptide) of the present invention.
- Examples of the host cell include Escherichia coli, Bacillus subtilis, yeast, insect cells, and animal cells. Are used.
- the cell membrane fraction refers to a cell membrane-rich fraction obtained by disrupting cells and then obtained by a method known per se.
- the cells can be disrupted by crushing the cells with a Potter-Elvehjem homogenizer, crushing with a Perling blender or a polytron (Kinematica), crushing with ultrasonic waves, pressing the cells from a thin nozzle while applying pressure with a French press, etc. Fracture by eruption is mentioned.
- centrifugal fractionation methods such as differential centrifugation and density gradient centrifugation are mainly used.
- cell lysate may be prepared at low speed (500 rpm to 3,000 rpm) for a short time (typically about 1 to 10 minutes).
- the membrane fraction is rich in the expressed protein (peptide) of the present invention and membrane components such as cell-derived phospholipids and membrane proteins.
- an appropriate protein (peptide) -containing membrane fraction of the present invention and a labeled test compound are required.
- the protein (peptide) -containing membrane fraction of the present invention may be a natural protein-containing membrane fraction of the present invention, or a recombinant protein (peptide) -containing membrane fraction of the present invention having an activity equivalent thereto. Minutes are desirable.
- equivalent activity means equivalent ligand binding activity, signal transduction action, and the like.
- a cell producing the protein (peptide) of the present invention or a membrane fraction thereof is suspended in a buffer suitable for the determination method.
- the protein (peptide) standard of the present invention is prepared by turbidity.
- the buffer may be any buffer that does not inhibit the binding between the protein of the present invention and its ligand, such as a phosphate buffer having a pH of 4 to 10 (preferably pH 6 to 8) and a buffer of Tris-HCl.
- surfactants such as CHAPS, Tween-80 TM (Kao-Atlas), digitonin, and dexcholate are used to buffer various proteins such as serum albumin and gelatin. Can also be added.
- a protease inhibitor such as PMSF, leptin, E-64 (manufactured by Peptide Research Laboratories), and peptide suptin can be added for the purpose of suppressing the degradation of the receptor and the ligand by the protease. 0.01 protein m.
- a test compound in which the count (B-NSB) obtained by subtracting the non-specific binding amount (NSB) from the total binding amount (B) exceeds 0 cpm is selected as a ligand (agonist) for the protein of the present invention or a salt thereof. can do.
- a cell stimulating activity mediated by the protein of the present invention for example, 'Acid release, acetylcholine release, intracellular Ca 2+ release, intracellular CAMP production, intracellular cGMP production, inositol phosphate production, cell membrane potential fluctuation, intracellular protein phosphorylation, c-fos activity Activity or activity for promoting pH reduction, etc.
- a cell stimulating activity mediated by the protein of the present invention for example, 'Acid release, acetylcholine release, intracellular Ca 2+ release, intracellular CAMP production, intracellular cGMP production, inositol phosphate production, cell membrane potential fluctuation, intracellular protein phosphorylation, c-fos activity Activity or activity for promoting pH reduction, etc.
- a known method or a commercially available measurement kit Specifically, first, cells producing the protein of the present invention, (peptide), are cultured in a multiwell plate or the like.
- the activity of inhibiting the production of MP can be detected as the activity of inhibiting the production of cells whose basal production has been increased by forskolin or the like.
- a kit for determining a compound having specific affinity for the protein of the present invention or a salt thereof comprises a protein (peptide) of the present invention, a cell producing the protein of the present invention or a membrane fraction thereof, and a protein of the present invention. It contains the culture supernatant of secreted cells.
- kits for determining a ligand (receptor) of the present invention include the following.
- CHO cells expressing the protein (peptide) of the present invention were subcultured on a 12-well plate in 5 ⁇ 10 5 Z-wells and cultured for 2 days at 37 ° C., 5% C 2 , and 95% air. (When the protein of the present invention is a secreted protein, the plate is coated with an antibody against the protein).
- Test compounds that are poorly soluble in water should be dissolved in dimethylformamide, DMSO, methanol, etc.
- the same as the labeling compound is prepared at a concentration 100 to 1,000 times higher.
- Examples of the ligand capable of binding to the membrane protein of the present invention or a salt thereof include substances specifically present in the brain, pituitary gland, kidney and the like. Physically, angiotensin, bombesin, canapinoids, cholecystokinin, glutamine, serotonin, melatonin, neuropeptide Y, obioid, pudding, vasoprescin, oxitocin, PACAP, secretin, glucagon, calcitonin, adreno, medutin, medutin , GHRH.
- oral tensin, TRH, pancreatic polypeptide, and galanin are used.
- the protein (peptide) of the present invention or (2) the protein (peptide) depends on the action of the compound.
- Can be used as a medicament such as an agent for preventing or treating diseases associated with dysfunction of the protein of the present invention.
- the protein (peptide) of the present invention when there is a patient who cannot expect the physiological action of the ligand (or the receptor) due to a decrease in the protein of the present invention in a living body (deficiency of the protein of the present invention), 1) the protein (peptide) of the present invention Is administered to the patient to replenish the amount of the protein of the present invention, or (2) the DNA encoding the protein (peptide) of the present invention is administered to the patient for expression, or (mouth) DNA encoding the protein (peptide) of the present invention is introduced into By transplanting the cells into the patient after the expression, the amount of the protein of the present invention in the body of the patient can be increased, and the effect of the ligand (or receptor) can be sufficiently exerted. That is, the protein (peptide) of the present invention or DNA encoding the same is useful as a safe and low toxic agent for the prophylaxis or treatment of diseases associated with dysfunction of the protein of the present invention.
- the protein of the present invention is highly expressed in white adipocytes during high-fat diet load stress, and its expression fluctuates depending on diet, stimulation with insulin resistance regulators, obesity / diabetes, and the like.
- Diseases related to the dysfunction of the protein of the present invention include abnormalities (insufficiency or enhancement) of adipocyte differentiation and Z or metabolic functions (particularly sugar / lipid metabolism).
- -Related diseases eg, obesity, diabetes, impaired glucose tolerance, arteriosclerosis, hypertension, hyperlipidemia, etc.).
- the protein (peptide) of the present invention and (2) the DNA encoding the protein (peptide) are pharmacologically acceptable, if necessary. It can be used as a prophylactic / therapeutic agent for diseases associated with dysfunction of the protein of the present invention after being mixed with a possible carrier to form a pharmaceutical composition.
- the pharmacologically acceptable carrier various organic or inorganic carrier substances commonly used as a drug substance are used, such as a solid preparation, a lubricant, a binder, a disintegrant, and a solvent in a liquid preparation. It is formulated as a solubilizer, suspending agent, isotonic agent, buffer, soothing agent, and the like. If necessary, pharmaceutical additives such as preservatives, antioxidants, coloring agents and sweeteners can also be used.
- excipients include lactose, sucrose, D-mannitol, D-sorbitol, starch, starch arsenide, dextrin, crystalline cellulose, low-substituted hydroxypropylcellulose, sodium carboxymethylcellulose, gum arabic, dextrin , Pullulan, light citric anhydride, synthetic citric acid aluminum, magnesium metasilicate, and the like.
- the lubricant include magnesium stearate, calcium stearate, talc, colloidal silica and the like.
- Preferred examples of the binder include starch arsenide, sucrose, gelatin, gum arabic, methylcellulose, carboxymethylcellulose, sodium carboxymethylcellulose, crystalline cellulose, sucrose, D_mannitol, trehalose, dextrin, pullulan, and hydroxypropyl Cellulose, hydroxypropylmethylcellulose, polyvinylpyrrolidone and the like can be mentioned.
- Preferred examples of the disintegrant include lactose, sucrose, starch, carboxymethylcellulose, carboxymethylcellulose calcium, croscarmellose sodium, carboxymethyl starch sodium, light caustic anhydride, and low-substituted hydroxypropylcellulose. No.
- Preferred examples of the solvent include water for injection, physiological saline, Ringer's solution, alcohol, propylene glycol, polyethylene glycol, sesame oil, corn oil, olive oil, cottonseed oil and the like.
- solubilizers include polyethylene glycol, propylene glycol, D-mannitol, trehalose, benzyl benzoate, ethanolyl, trisaminomethane, cholesterol, triethanolamine, sodium carbonate, and quinic acid.
- solubilizers include polyethylene glycol, propylene glycol, D-mannitol, trehalose, benzyl benzoate, ethanolyl, trisaminomethane, cholesterol, triethanolamine, sodium carbonate, and quinic acid.
- suspending agent examples include surfactants such as stearyltriethanolamine, sodium lauryl sulfate, laurylaminopropionic acid, lecithin, benzal conidum chloride, benzethonium chloride and glyceryl monostearate; Hydrophilic polymers such as polyvinyl alcohol, polyvinylpyrrolidone, sodium carboxymethylcellulose, methylcellulose, hydroxymethylcellulose, hydroxyethylcellulose, and hydroxypropylcellulose; polysorbates, polyoxyethylene hydrogenated castor oil, etc. Can be surfactants such as stearyltriethanolamine, sodium lauryl sulfate, laurylaminopropionic acid, lecithin, benzal conidum chloride, benzethonium chloride and glyceryl monostearate; Hydrophilic polymers such as polyvinyl alcohol, polyvinylpyrrolidone, sodium carboxymethylcellulose, methylcellulose, hydroxymethylcellulose, hydroxyeth
- Preferred examples of the tonicity agent include sodium chloride, glycerin, D-mannitol, D-sorbitol, glucose and the like.
- Preferred examples of the buffer include buffers such as phosphate, acetate, carbonate, and citrate.
- Preferred examples of the soothing agent include benzyl alcohol and the like.
- Preferable examples of the preservative include paraoxybenzoic acid esters, chlorobutanol, benzyl alcohol, phenethyl alcohol, dehydroacetic acid, sorbic acid and the like.
- Suitable examples of the antioxidant include sulfite, ascorbate and the like.
- coloring agents include water-soluble edible tar dyes (e.g., edible pigments such as edible red Nos. 2 and 3, edible yellows 4 and 5, edible blues 1 and 2, water-insoluble Lake dyes (eg, the aluminum salt of the water-soluble edible tar dye, etc.);
- water-soluble edible tar dyes e.g., edible pigments such as edible red Nos. 2 and 3, edible yellows 4 and 5, edible blues 1 and 2, water-insoluble Lake dyes (eg, the aluminum salt of the water-soluble edible tar dye, etc.);
- Preferred examples of the sweetener include saccharin sodium, dipotassium glycyrrhizinate, aspartame, stevia and the like.
- Examples of the dosage form of the pharmaceutical composition include oral preparations such as tablets, capsules (including soft capsules and microcapsules), granules, powders, syrups, emulsions, and suspensions; and injections (eg, Subcutaneous injections, intravenous injections, intramuscular injections, intraperitoneal injections, etc.), external preparations (eg, nasal preparations, transdermal preparations, ointments, etc.), suppositories (eg, rectal suppositories, Parenteral preparations such as vaginal suppositories, pellets, drops, and sustained-release preparations (eg, sustained-release microcapsules).
- oral preparations such as tablets, capsules (including soft capsules and microcapsules), granules, powders, syrups, emulsions, and suspensions
- injections eg, Subcutaneous injections, intravenous injections, intramuscular injections, intraperitoneal injections, etc.
- external preparations
- the pharmaceutical composition can be produced by a method commonly used in the field of formulation technology, for example, the method described in the Japanese Pharmacopoeia and the like. Hereinafter, the specific production method of the drug product will be described in detail.
- the content of the active ingredient in the pharmaceutical composition varies depending on the dosage form, the dose of the active ingredient and the like, but is, for example, about 0.1 to 100% by weight.
- oral preparations include, as active ingredients, excipients (eg, lactose, sucrose, starch, D-mannitol, etc.), disintegrants (eg, carboxymethylcellulose calcium, etc.), binders (eg, pregelatinized starch). , Gum arabic, carboxymethylcellulose, hydroxypropylcellulose, polyvinylpyrrolidone, etc.) or lubricants (eg, talc, magnesium stearate, polyethylene glycol 600, etc.) and compression molding Then, if necessary, taste It is produced by coating with a coating base by a method known per se for the purpose of soaking, enteric coating or persistence.
- excipients eg, lactose, sucrose, starch, D-mannitol, etc.
- disintegrants eg, carboxymethylcellulose calcium, etc.
- binders eg, pregelatinized starch.
- binders eg, pregelatinized starch.
- binders
- the coating base examples include a sugar coating base, a water-soluble film coating base, an enteric film coating base, a sustained release film coating base, and the like.
- sucrose is used, and one or more kinds selected from talc, precipitated calcium carbonate, gelatin, gum arabic, pullulan, carnauba wax and the like may be used in combination.
- water-soluble film coating base examples include cellulosic polymers such as hydroxypropylcellulose, hydro'xypropylmethylcellulose, hydroxyethylcellulose, and methylhydroxyethylcellulose; polyvinylacetate-l-ethylacetylaminoacetate. And synthetic polymers such as aminoalkyl methacrylate copolymer E (Eudragit E (trade name), Rohm Pharma Co., Ltd.) and polyvinylpyrrolidone; and polysaccharides such as pullulan.
- cellulosic polymers such as hydroxypropylcellulose, hydro'xypropylmethylcellulose, hydroxyethylcellulose, and methylhydroxyethylcellulose
- polyvinylacetate-l-ethylacetylaminoacetate examples include polyvinylacetate-l-ethylacetylaminoacetate.
- synthetic polymers such as aminoalkyl methacrylate copolymer E (Eudragit E (trade name), Rohm Pharma
- enteric film coating base examples include cellulosic polymers such as hydroxypropylmethylcellulose phthalate, hydroxypropylmethylcellulose acetate succinate, carboxymethylethylcellulose, and cellulose acetate phthalate; Copolymer L [Eudragit L (trade name), Rohm Pharma Co., Ltd.], Methacrylic acid copolymer LD [Eudragit L-1 30 D55 (trade name), Rohm Pharma Co., Ltd.], Methacrylic acid copolymer S [Eudragit S (trade name) And Rohm Pharma Co.]; natural products such as shellac.
- cellulosic polymers such as hydroxypropylmethylcellulose phthalate, hydroxypropylmethylcellulose acetate succinate, carboxymethylethylcellulose, and cellulose acetate phthalate
- Copolymer L Eudragit L (trade name), Rohm Pharma Co., Ltd.]
- Methacrylic acid copolymer LD Eudragit L-1 30 D55 (
- sustained-release film coating base examples include cellulosic polymers such as ethyl cellulose; aminoalkyl methacrylate copolymer RS (Eudragit RS (trade name), Rohm Pharma Co., Ltd.), ethyl acrylate, methacrylic acid An acrylic acid polymer such as a methyl copolymer suspension [Eudragit NE (trade name) Rohm Pharma Co., Ltd.].
- cellulosic polymers such as ethyl cellulose; aminoalkyl methacrylate copolymer RS (Eudragit RS (trade name), Rohm Pharma Co., Ltd.), ethyl acrylate, methacrylic acid
- An acrylic acid polymer such as a methyl copolymer suspension [Eudragit NE (trade name) Rohm Pharma Co., Ltd.].
- the above-mentioned coating bases are used by mixing two or more kinds thereof at an appropriate ratio. You may. Further, at the time of coating, a light-shielding agent such as titanium oxide, iron sesquioxide and the like may be used.
- Injectables contain active ingredients as dispersants (eg, polysorbate 80, polyoxyethylene hydrogenated castor oil 60, etc., polyethylene glycol, carboxymethylcellulose, sodium alginate, etc.), preservatives (eg, methylparaben, pulpylparaben, benzyl) Alcohol, chlorobutanol, phenol, etc.), isotonic agents (eg, sodium chloride, glycerin, D-mannitol, D-sorbitol, dextrose, etc.) and aqueous solvents (eg, distilled water, physiological saline, Ringer's solution) It is manufactured by dissolving, suspending or emulsifying in an oily solvent (eg, vegetable oil such as olive oil, sesame oil, cottonseed oil, corn oil, propylene glycol, etc.).
- an oily solvent eg, vegetable oil such as olive oil, sesame oil, cottonseed oil, corn oil, propylene glycol, etc.
- additives such as a solubilizing agent (eg, sodium salicylate, sodium acetate, etc.), a stabilizer (eg, human serum albumin, etc.), a soothing agent (eg, benzyl alcohol, etc.) may be used.
- a solubilizing agent eg, sodium salicylate, sodium acetate, etc.
- a stabilizer eg, human serum albumin, etc.
- a soothing agent eg, benzyl alcohol, etc.
- the injection solution is usually filled in a suitable ampoule.
- the preparations obtained in this way are safe and low toxic, for example, against mammals (eg humans, rats, puppies, higgs, bushes, puppies, cats, dogs, sal, etc.). Can be administered.
- mammals eg humans, rats, puppies, higgs, bushes, puppies, cats, dogs, sal, etc.
- the DNA of the present invention may be used alone or after being inserted into an appropriate expression vector such as a retrovirus vector, an adenovirus vector, or an adeno-associated virus vector. It can also be administered according to the procedure. Further, the DNA of the present invention can be administered as it is or together with an auxiliary agent for promoting uptake, using a gene gun or a catheter such as a hydrogel catheter.
- an appropriate expression vector such as a retrovirus vector, an adenovirus vector, or an adeno-associated virus vector. It can also be administered according to the procedure. Further, the DNA of the present invention can be administered as it is or together with an auxiliary agent for promoting uptake, using a gene gun or a catheter such as a hydrogel catheter.
- the dose of the protein (peptide) of the present invention varies depending on the administration subject, target organ, symptoms, administration method, and the like.
- about 0.1 to 10 Omg per day preferably about 1.0 to 5 Omg, more preferably about 1.0 to 2 Omg per day.
- the single dose varies depending on the administration subject, target organ, symptoms, administration method, etc.
- about 0.01 to 3 Omg per day preferably about 0.1 to 20 mg, more preferably about 0.1 to 1 Omg per day It is convenient to administer the degree. Even when the subject to be administered is not human, the dose can be administered in terms of 60 kg of body weight.
- the dosage of the DNA of the present invention varies depending on the administration target, target organ, symptoms, administration method, and the like.
- oral administration in general, for example, in a patient with abnormal glucose and lipid metabolism (as 60 kg) Is about 0.1 to 10 Omg per day, preferably about 1.0 to 5 Omg, more preferably about 1.0 to 20 mg.
- parenteral administration the single dose varies depending on the administration subject, target organ, symptoms, administration method, and the like. (As O kg), it is convenient to administer about 0.01 to 3 Omg per day, preferably about 0.1 to 20 mg, more preferably about 0 :! to 1 Omg per day. Even when the subject to be administered is not a human, the dose can be administered in terms of 60 kg of body weight.
- Antibodies against the protein (peptide) of the present invention may be used for signal transduction functions involving the protein of the present invention, for example, cell stimulating activity mediated by the protein of the present invention (eg, arachidonic acid release, acetylcholine release, intracellular Ca 2+ release, Inhibition of intracellular cAMP production, intracellular cGMP production, inositol phosphate production, cell membrane potential fluctuation, intracellular protein phosphorylation, activation of c-fos, activity to suppress or decrease pH etc.) It can be activated (ie neutralized).
- cell stimulating activity mediated by the protein of the present invention eg, arachidonic acid release, acetylcholine release, intracellular Ca 2+ release, Inhibition of intracellular cAMP production, intracellular cGMP production, inositol phosphate production, cell membrane potential fluctuation, intracellular protein phosphorylation, activation of c-fos, activity to suppress or decrease pH etc.
- an antisense nucleic acid (including a double-stranded oligo RNA having lipozyme RNAi activity) of the protein of the present invention or its partial peptide is used for transcription of the protein gene of the present invention, processing of the transcript, and / or mRNA.
- the expression of the protein of the present invention can be inhibited. Therefore, (1) the antibody of the present invention or (2) the antisense nucleic acid of the present invention can be used as a medicament such as an agent for preventing or treating a disease associated with overexpression of the protein of the present invention.
- the protein of the present invention is highly expressed in white adipocytes at the time of high-fat diet stress, and its expression fluctuates depending on the diet, stimulation with insulin resistance regulators, obesity, diabetes, and other pathological conditions.
- Diseases associated with the overexpression of the protein of the present invention include adipocyte differentiation and abnormal or impaired metabolic functions (especially sugar or lipid metabolism) (insufficiency or enhancement).
- -Related diseases eg, obesity, diabetes, impaired glucose tolerance, arteriosclerosis, hypertension, hyperlipidemia, etc.).
- the antibody of the present invention and the antisense nucleic acid of the present invention can be formulated in the same manner as in the aforementioned “agent for preventing and treating diseases associated with dysfunction of the protein of the present invention”. Further, the antisense nucleic acid can be administered as it is by using a gene gun or a catheter such as a hydrogel catheter.
- the dose of the antibody of the present invention varies depending on the administration subject, target organ, symptom, administration method, and the like.
- oral administration in general, for example, patients with abnormal glucose and lipid metabolism (assuming a body weight of 60 kg) About 0.1 to 100 mg, preferably about 1.0 to 5 Omg, more preferably about 1.0 to 20 mg per day.
- parenteral administration the single dose varies depending on the subject of administration, target organ, symptoms, administration method, etc.
- body weight 6 (As O kg) it is convenient to administer about 0.01 to 30 mg per day, preferably about 0.1 to 20 mg, more preferably about 0.1 to 1 Omg per day.
- the dose can be administered in terms of 60 kg of body weight.
- the dosage of the antisense nucleic acid of the present invention varies depending on the administration subject, target organ, symptoms, administration method, and the like. ), About 0.1 to 10 Omg per day, preferably about 1.0 to 5 Omg, more preferably about 1.0 to 20 mg. In the case of parenteral administration, the single dose varies depending on the administration target, target organ, symptoms, administration method, and the like. 6 O kg), about 0.01 to 30 mg / day, preferably about 0.1 to 20 mg / day. More preferably, it is convenient to administer about 0.1 to 1 Omg. Even when the target of administration is other than human, the dose can be administered in terms of 60 kg of body weight.
- the nucleic acid containing the nucleotide sequence encoding the protein of the present invention or a part thereof can be used as a probe to obtain a mammal (eg, It is possible to detect abnormalities (DNA abnormalities) in the DNA or mRNA encoding the protein of the present invention in humans, rats, rabbits, rabbits, sheep, bushfishes, horses, cats, dogs, monkeys, etc.).
- the DNA or mRNA is useful as a diagnostic agent for a gene such as damage, mutation, or reduced expression of the DNA or mRNA, and increased or excessive expression of the DNA or mRNA.
- the above-described genetic diagnosis using the sense nucleic acid or the antisense nucleic acid of the present invention can be performed, for example, by the known Northern hybridization or PCR-SSCP method (Genomics, Vol. 5, pp. 874-879 (1989) Proceedings of the National Academy of Sciences of the United States of America, Vol. 86, 2766-27 70 Page (1989)).
- a decrease in the expression of the protein of the present invention when a decrease in the expression of the protein of the present invention is detected by Northern hybridization, it means that, for example, the subject is suffering from a disease associated with dysfunction of the protein or is likely to suffer from the disease in the future. Can be diagnosed. Conversely, when overexpression of the protein of the present invention is detected by, for example, Northern hybridization, for example, the patient is suffering from a disease associated with hyperactivity of the protein or will suffer from the disease in the future It can be diagnosed that the probability is high.
- the protein of the present invention is highly expressed in white adipocytes at the time of high-fat diet stress, and its expression fluctuates depending on the diet, stimulation with insulin resistance regulators, obesity, diabetes, and other pathological conditions. Do not affect adipocyte differentiation
- the sense nucleic acid or antisense nucleic acid of the present invention can be used for diseases involving abnormalities (insufficiency or enhancement) of adipocyte differentiation and Z or metabolic functions (especially glucose / lipid metabolism) (eg, obesity, diabetes, It is useful for diagnosis of impaired glucose tolerance, arteriosclerosis, hypertension, hyperlipidemia, etc.).
- the sense or antisense nucleic acid of the present invention By using the sense or antisense nucleic acid of the present invention as a probe, it can be used for screening a compound that changes the expression level of a gene encoding the protein of the present invention. Also, a compound that changes the expression level of the gene encoding the protein of the present invention can be screened by performing RT-PCR using the sense nucleic acid and the antisense nucleic acid of the present invention as a pair of primers. be able to.
- the present invention relates to, for example, (i) a non-human mammal's (2) blood, (2) a specific organ, (3) a tissue or cell isolated from an organ, or (ii) a protein of the present invention contained in a transformant or the like.
- the amount of mRNA encoding the protein (peptide) of the present invention is measured as follows.
- non-human mammals e.g., mice, rats, egrets, sheep, sheep, bush, puppies, cats, dogs, monkeys, etc .; more specifically, obese mice, diabetic mice, hypertension
- Drugs eg, antiobesity drugs, antidiabetic drugs, antihypertensive drugs, vasoactive drugs, anticancer drugs, etc.
- physical stress e.g, flooding stress, electric shock
- Blood or specific organs (eg, brain, liver, kidney, etc.) or tissues isolated from the organs (eg, brown or white adipose tissue, etc.) ) Or cells (such as fat cells).
- MRNA encoding the protein of the present invention contained in the obtained cells for example, MRNA can be extracted from cells or the like by an ordinary method, and quantified by using a technique such as TaqMan PCR, or analyzed by performing Northern blotting by a method known per se.
- a transformant expressing the protein (peptide) of the present invention is prepared according to the above-mentioned method, and mRNA encoding the protein (peptide) of the present invention contained in the transformant is similarly quantified. , Can be analyzed.
- test compound is administered simultaneously with the physical stress, and after a lapse of a certain period of time after the administration (30 minutes to 3 days, preferably 1 hour to 2 days, more preferably 1 hour to 24 hours), It can be carried out by quantifying and analyzing the amount of mRNA encoding the protein of the present invention contained in the cells,
- test compound When culturing the transformant according to a conventional method, the test compound is mixed in a medium, and after culturing for a certain period of time (1 to 7 days, preferably 1 to 3 days, more preferably 2 days to Three days later), the amount of mRNA encoding the protein (peptide) of the present invention contained in the transformant can be determined and analyzed.
- a kit for screening a compound that changes the expression level of a gene encoding the protein of the present invention includes: (a) a probe comprising a sense and / or antisense nucleic acid of the present invention, preferably a double-stranded oligo DNA; or (b) A primer set comprising the sense nucleic acid of the present invention and the antisense nucleic acid of the present invention is characterized in that the primer set is constituted.
- the probe those labeled with RI, fluorescence, enzyme, or the like by a conventional method are used.
- the screening kit may further comprise an RNA extraction reagent and And / or tools (eg, extraction buffer, spin column, etc.), reagents for PCR or Northern hybridization, and Z or tools (eg, dNTPs, PCR reaction buffer, heat-resistant DNA polymerase, etc.), of the present invention
- RNA extraction reagent and And / or tools eg, extraction buffer, spin column, etc.
- reagents for PCR or Northern hybridization eg, dNTPs, PCR reaction buffer, heat-resistant DNA polymerase, etc.
- Z or tools eg, dNTPs, PCR reaction buffer, heat-resistant DNA polymerase, etc.
- the compound or a salt thereof obtained by using the screening method of the present invention is a compound having an action of changing the expression level of a gene encoding the protein of the present invention.
- the cell stimulating activity through the interaction between the protein of the present invention and its receptor (or ligand) (for example, arachidonic acid release, acetylcholine release, intracellular Ca 2+ release, cell Activity to promote or suppress intracellular cAMP production, intracellular cGMP production, wild boar! Phosphoric acid production, cell membrane potential fluctuation, intracellular protein phosphorylation, activation of c-fos, decrease in PH, etc.
- the receptor for example, arachidonic acid release, acetylcholine release, intracellular Ca 2+ release, cell Activity to promote or suppress intracellular cAMP production, intracellular cGMP production, wild boar! Phosphoric acid production, cell membrane potential fluctuation, intracellular protein phosphorylation, activation of c-fos, decrease in PH, etc.
- mouth
- Examples of the compound include peptides, proteins, non-peptidic compounds, synthetic compounds, and fermentation products. These compounds may be novel compounds or known compounds.
- the compound that enhances the cell stimulating activity is useful as a safe and low-toxic drug for enhancing the physiological activity of the protein of the present invention.
- the compound that attenuates the cell stimulating activity is useful as a safe and low toxic drug for decreasing the physiological activity of the protein of the present invention.
- a compound or a salt thereof obtained by the above-mentioned screening method is used as a medicament, it can be formulated as in the above-mentioned "agent for preventing / treating a disease associated with dysfunction of the protein of the present invention".
- the preparations obtained in this way are safe and low toxic, for example, against mammals (eg humans, rats, puppies, higgs, bushes, puppies, cats, dogs, sal, etc.). Can be administered.
- mammals eg humans, rats, puppies, higgs, bushes, puppies, cats, dogs, sal, etc.
- the dose of the compound or a salt thereof varies depending on the administration subject, target organ, symptoms, administration method, and the like.
- the dose is about 0.1 to 100 mg, preferably about 1.0 to 50 mg, more preferably about 1.0 to 20 mg per day.
- the single dose varies depending on the administration target, target organ, symptoms, administration method, and the like. (As 60 kg), it is convenient to administer about 0.01 to 30 mg, preferably about 0.1 to 2 Omg, more preferably about 0.1 to 1 Omg per day. Even when animals to be administered are animals other than humans, the dose can be administered per 60 kg of body weight.
- a preventive / therapeutic agent for various diseases containing a compound that alters the expression level of the gene encoding the protein of the present invention
- the protein of the present invention is highly expressed in white adipocytes at the time of high-fat diet load stress, and its expression fluctuates depending on the condition such as diet, stimulation with an insulin resistance regulator, obesity and diabetes, and the like. Since the fluctuation of the expression affects the differentiation of adipocytes, it is considered that they play an important role in the regulation of adipocyte differentiation and / or metabolic function.
- compounds that alter the expression level of the gene encoding the protein of the present invention include diseases associated with abnormalities (insufficiency or enhancement) of adipocyte differentiation and / or metabolic functions (especially sugar / lipid metabolism) (for example, It can be used as a prophylactic / therapeutic agent for obesity, diabetes, impaired glucose tolerance, arteriosclerosis, hypertension, hyperlipidemia, etc.
- prophylactic / therapeutic agent for a disease associated with dysfunction or enhancement of the protein of the present invention the same as the above-mentioned "prophylactic / therapeutic agent for a disease associated with the dysfunction of the protein of the present invention" is used.
- prophylactic / therapeutic agent for a disease associated with the dysfunction of the protein of the present invention Can be formulated.
- the preparations obtained in this way are safe and low toxic, so they can be used, for example, in mammals (eg humans, rats, puppies, sheep, shreds, poultry, cats, dogs, sal, etc.). Can be administered.
- mammals eg humans, rats, puppies, sheep, shreds, poultry, cats, dogs, sal, etc.
- the dose of the compound or a salt thereof varies depending on the administration subject, target organ, symptoms, administration method, and the like.
- oral administration in general, for example, a patient having abnormal glucose and lipid metabolism (assuming a body weight of 6 O kg) About 0.1 to 100 per day mg, preferably about 1.0-5 Omg, more preferably about 1.0-20 mg.
- parenteral administration the single dose varies depending on the subject of administration, target organ, symptoms, administration method, etc.
- the subject to be administered is an animal other than a human, the dose can be administered in terms of the body weight per 6 O kg.
- the protein (peptide) of the present invention has a binding property to a ligand (or receptor) for the protein of the present invention, the concentration of the ligand (or receptor) in a living body can be quantified with high sensitivity. it can.
- the ligand (or receptor) quantification method of the present invention can be performed, for example, in combination with a competition method. That is, the ligand (or receptor) concentration in the sample can be measured by bringing the sample into contact with the protein (peptide) of the present invention. Specifically, for example, the method can be carried out according to the method described in (1) or (2) below or a method analogous thereto. (1) Hiro Irie "Radio No Tsutsui" (Kodansha, published in 1974)
- a compound eg, agonist, angonist, etc.
- the protein of the present invention By using the protein (peptide) of the present invention or constructing an expression system for the recombinant protein (peptide) of the present invention, and using the affinity system using the expression system, the protein of the present invention and its Compounds (eg, peptides, proteins, non-peptide compounds, synthetic compounds, fermentation products, etc.) that change the binding properties of ligands (or receptors) or salts thereof can be efficiently screened.
- Compounds eg, peptides, proteins, non-peptide compounds, synthetic compounds, fermentation products, etc.
- Such compounds via a receptor-stimulating activity (e.g., Arakidon acid release, acetylcholine release, intracellular C a 2 + release, intracellular C AM P production, intracellular c GM P product, inositol
- a receptor-stimulating activity e.g., Arakidon acid release, acetylcholine release, intracellular C a 2 + release, intracellular C AM P production, intracellular c GM P product, inositol
- a receptor-stimulating activity e.g., Arakidon acid release, acetylcholine release, intracellular C a 2 + release, intracellular C AM P production, intracellular c GM P product, inositol
- the compound (a) is preferably screened by the ligand determination method described in (1) above.
- the present invention relates to (i) a case where the protein (peptide) of the present invention is brought into contact with its ligand (or receptor); and (ii) a protein (peptide) of the present invention and its ligand (or receptor). And a ligand of the present invention, which is compared with the case of contact with a test compound.
- the screening method of the present invention is characterized in that in (i) and (ii), the amount of ligand (or receptor) bound to the protein of the present invention, the cell stimulating activity and the like are measured and compared.
- the present invention provides
- a method for screening a compound to be changed or a salt thereof (2)
- the labeled ligand (or receptor) is added to a cell producing the protein of the present invention or its membrane fraction, or an extracellular fluid or cell culture supernatant (in this case, for example, the antibody of the present invention described above is used).
- an immobilized solid phase such as a cell culture plate
- the labeled ligand (or receptor) and a test compound produce the protein of the present invention.
- the labeled ligand (or receptor) is secreted into the protein (peptide) of the present invention expressed on the cell membrane by culturing the transformant containing the DNA of the present invention or the culture supernatant.
- the protein (peptide) of the present invention in this case, for example, the protein (peptide) of the present invention is immobilized using a solid phase (cell culture plate or the like) on which the antibody of the present invention is immobilized).
- the labeled ligand (or receptor) and the test compound are expressed on the cell membrane by culturing a transformant containing the DNA of the present invention.
- Binding amount of labeled ligand (or receptor) to protein (peptide) when brought into contact with secreted protein (peptide) of the present invention Measured, compared protein and a test compound to the binding Ru varied with its ligand (or receptions evening I) of the present invention which is characterized in that,
- a compound that activates the protein of the present invention for example, a ligand for the membrane protein of the present invention, etc.
- a compound that is activated by the protein of the present invention for example, a receptor for the secretory protein of the present invention, etc.
- the protein of the present invention When the protein of the present invention is brought into contact with cells expressing on the cell membrane or a culture supernatant from which the protein of the present invention is secreted, it is activated by a compound that activates the protein of the present invention or by the protein of the present invention.
- Cell stimulatory activity via receptor receptor e.g., arachidonic acid release, acetylcholine release, intracellular Ca2 + release, intracellular cAMP production, intracellular cGMP production, inositol phosphate production, Cell membrane potential fluctuations, phosphorylation of intracellular proteins, activation of c-fos, activity to suppress or decrease pH, etc.
- receptor receptor e.g., arachidonic acid release, acetylcholine release, intracellular Ca2 + release, intracellular cAMP production, intracellular cGMP production, inositol phosphate production, Cell membrane potential fluctuations, phosphorylation of intracellular proteins, activation of c-fos, activity to suppress or decrease pH, etc.
- a compound that activates the protein of the present invention for example, a ligand for the membrane protein of the present invention or a compound that is activated by the protein of the present invention (for example, receptor for the secretory protein of the present invention)
- the protein of the present invention expressed on the cell membrane by culturing the transformant containing the DNA of the present invention
- (Peptide) or a transformant containing the DNA of the present invention is cultured to contact the protein (Peptide) of the present invention secreted in the culture supernatant, and activates the protein of the present invention.
- Receptor-mediated cell stimulating activity eg, arachidonic acid
- any protein containing the above-described protein of the present invention or a partial peptide thereof or a salt thereof may be used.
- Produces the protein of the present invention Cell membrane fractions or extracellular fluids of living mammalian organs are preferred.
- human-derived proteins (peptides) of the present invention and the like which are expressed in large amounts using recombinants are suitable for screening.
- the above-mentioned method is used for producing the protein (peptide) of the present invention, but it is preferably carried out by expressing the DNA of the present invention in mammalian cells or insect cells.
- CDNA is used as the DNA fragment encoding the target protein portion, but is not necessarily limited thereto.
- a gene fragment or a synthetic DNA may be used.
- the DNA fragment In order to introduce a DNA fragment encoding the protein of the present invention or a partial peptide thereof into host animal (insect) cells and express them efficiently, the DNA fragment must be a promoter fragment derived from SV40. , Retrovirus promoter, meta-oral thionine promoter, human heat shock promoter, cytomegalovirus promoter, SRo! Promoter, nucleopolyhedrovirus belonging to baculovirus with insect host
- NPV nuclear polyhedrosis virus
- the protein (peptide) of the present invention used in the screening method of the present invention may be the protein (peptide) of the present invention purified according to a method known per se, or the protein (peptide) of the present invention. It may be in the form of a cell to be produced or a cell membrane fraction thereof, or a culture supernatant of a cell secreting the protein (peptide) of the present invention.
- the cells when cells that produce the protein (peptide) of the present invention are used, the cells may be immobilized with daltaraldehyde, formalin, or the like.
- the immobilization method can be performed according to a method known per se.
- the cell that produces the protein (peptide) of the present invention refers to a host cell that expresses the protein (peptide) of the present invention. Examples of the host cell include Escherichia coli, Bacillus subtilis, yeast, insect cells, and animal cells. Used.
- the cell membrane fraction refers to a cell membrane-rich fraction obtained by disrupting cells and then obtained by a method known per se.
- the cells can be crushed by crushing the cells with a Potter-Elvehj em-type homogenizer, crushing with a pellet blender or polytron (Kinematica), crushing with an ultrasonic wave, pressing the cells while applying pressure with a French press, etc. Crushing by ejecting from a thin nozzle is mentioned.
- centrifugal fractionation methods such as differential centrifugation and density gradient centrifugation are mainly used.
- the cell lysate is centrifuged at a low speed (500 rpm to 300 rpm) for a short time (usually about 1 to 10 minutes), and the supernatant is further centrifuged at a high speed (150 rpm to 1000 rpm). Spin at 30,000 rpm for 30 minutes to 2 hours, and use the resulting precipitate as the membrane fraction.
- the membrane fraction is rich in the expressed protein (peptide) of the present invention and membrane components such as cell-derived phospholipid / membrane proteins.
- the protein-containing fraction of the present invention is preferably a natural protein-containing fraction of the present invention, or a recombinant protein-containing fraction of the present invention having an activity equivalent thereto.
- “equivalent activity” means equivalent ligand binding activity, signal information transduction action and the like.
- Labeled ligands include labeled ligand, labeled ligand analog And the like. For example, ligands labeled with [ 3 H], C 125 I], [ 14 C], C 35 S] are used.
- the protein (peptide) preparation of the present invention is prepared by suspending the suspension in a buffer.
- Any buffer may be used as long as it does not inhibit the binding between the protein of the present invention and its ligand, such as a phosphate buffer of pH 4 to 10 (preferably pH 6 to 8) and a buffer of tris-hydrochloride.
- surfactants such as CHAPS, Tween-80 TM (Kao-Atlas), digitonin, and dexcholate can be added to the buffer for the purpose of reducing non-specific binding.
- a proteinase inhibitor such as PMSF, leptin, E-64 (manufactured by Peptide Research Laboratories), pepstatin and the like can be added for the purpose of suppressing the degradation of the receptor and ligand by the protease.
- the reaction is carried out at about 0 ° C to 5 Ot :, preferably at about 4 ° C to 37 ° C, for about 20 minutes to 24 hours, preferably for about 30 minutes to 3 hours.
- the solution is filtered through a glass fiber filter or the like, washed with an appropriate amount of the same buffer, and the radioactivity remaining on the glass fiber filter is measured using a liquid scintillation counter or an air counter.
- the specific binding amount (B—NSB) The test compound that is 50% or less can be selected as a candidate substance having a competitive inhibitory ability.
- a cell stimulating activity mediated by the protein of the present invention for example, arachidonic acid
- acetylcholine release for example, acetylcholine release
- intracellular Ca release for example, acetylcholine
- intracellular CAMP generation for example, acetylcholine
- intracellular cGMP generation for example, inositol
- cells that produce the protein (peptide) of the present invention are cultured on a multi-well plate or the like. Before conducting screening, replace the cells with fresh medium or an appropriate buffer that is not toxic to cells, add test compounds, etc., incubate for a certain period of time, and extract cells or supernatant. And the products generated are quantified according to the respective methods. If the production of a substance (for example, arachidonic acid) as an indicator of cell stimulating activity is difficult to perform due to the presence of a degrading enzyme contained in cells, it may be possible to add an inhibitor against the degrading enzyme to perform the assay. Good. In addition, activities such as inhibition of cAMP production can be detected as an activity of inhibiting production of cells whose basal production has been increased by forskolin or the like.
- a substance for example, arachidonic acid
- the cell that expresses the protein (peptide) of the present invention is preferably a cell line that produces a natural type of the membrane protein of the present invention, or a cell line that expresses the aforementioned recombinant protein (peptide) of the present invention.
- test compounds for example, peptides, proteins, non-peptidic compounds, synthetic compounds, fermentation products, cell extracts, plant extracts, animal tissue extracts, etc. are used. Or a known compound.
- a method for screening a compound or a salt thereof that alters the binding property between the protein of the present invention and its ligand (or receptor) was specifically described by taking the case where the protein of the present invention is a membrane protein, Even when the protein of the present invention is a secretory protein, those skilled in the art can easily screen for a compound that alters the binding properties between the secretory protein of the present invention and its receptor by applying the above-described method.
- the protein of the present invention and a compound having specific affinity for the protein (ligand or the like) Screening kit for a compound or a salt thereof that alters the binding of the protein or the peptide of the present invention, a cell producing the protein (peptide) of the present invention, a membrane fraction thereof, or the present invention. It contains the culture supernatant of cells that secrete proteins (peptides).
- Examples of the screening kit of the present invention include the following.
- CHO cells expressing the protein (peptide) of the present invention were subcultured on a 12-well plate in 5 ⁇ 10 5 Z-wells, and cultured for 2 days in 37t :, 5% CO 2 , 95% air ( When the protein (peptide) of the present invention is secreted, the plate is coated with an antibody against the protein).
- proteoribosomes in which the receptor protein was embedded in a ribosome membrane having an appropriate lipid composition were suspended in an appropriate dispersion medium (water, PBS, etc.), and stored in step 4. Those can also be used.
- Measurement method (1) After washing the protein (peptide) expression CHO cells of the present invention cultured on a 12-well tissue culture plate twice with the assay buffer lm1, (if the protein ( ⁇ peptide) of the present invention is secreted, after the cells and removed after plating the culture supernatant was washed similarly with assay buffer) is added 490 1 of assay buffer to each well ⁇ test compound solution 2 10- 3 ⁇ 10- 1Q M After adding 51, add 5 ⁇ 1 of labeled ligand (or receptor) and react at room temperature for 1 hour. A supplementary 5 ⁇ 1 10_ 3 Micromax ligand (or LES Scepter) standard solution in place of the test compound to determine the amount of non-specific binding.
- a compound or a salt thereof obtained by using the above-described screening method or screening kit has an effect of changing the binding property between the protein of the present invention and a compound (ligand or receptor) having specific affinity for the protein.
- cell stimulating activity eg, arachidonic acid release, acetylcholine release, intracellular Ca 2+ release, intracellular cAMP production, etc.
- A) a compound that does not have the cell stimulating activity a so-called antagonist against the receptor of the membrane protein of the present invention or the secretory protein of the present invention
- a protein of the present invention and its ligand or (2) a compound that decreases the binding force between the protein of the present invention and its ligand (or receptor).
- Examples of the compound include peptides, proteins, non-peptidic compounds, synthetic compounds, and fermentation products. These compounds may be novel compounds or known compounds.
- the agonist against the membrane protein of the present invention (or the receptor for the secretory protein of the present invention) has the same action as the physiological activity of the ligand for the membrane protein of the present invention (or the secretory protein of the present invention for the receptor). Therefore, it is useful as a safe and low toxic drug depending on the ligand activity.
- An antagonist to the membrane protein of the present invention can suppress the physiological activity of the ligand for the membrane protein of the present invention (or the secretory protein of the present invention for one receptor). It is useful as a safe and low toxic drug for suppressing the ligand activity.
- the compound that enhances the binding between the membrane protein of the present invention and its ligand (or the secretory protein of the present invention and its receptor) is a ligand for the membrane protein of the present invention (or the secretory protein of the present invention against receptor Yuichi). It is useful as a safe and low toxic drug for enhancing the physiological activity of (protein).
- the compound that decreases the binding force between the membrane protein of the present invention and its ligand has the ligand for the membrane protein of the present invention (or the secretory protein of the present invention for the receptor). It is useful as a safe and low toxic drug for reducing physiological activity.
- the preparations obtained in this way are safe and have low toxicity, for example, It can be administered to a substance (eg, human, rat, rabbit, sheep, pig, pig, cat, cat, dog, sal).
- a substance eg, human, rat, rabbit, sheep, pig, pig, cat, cat, dog, sal.
- the dose of the compound or a salt thereof varies depending on the administration subject, target organ, symptom, administration method and the like.
- the single dose is although it depends on the administration target, target organ, symptoms, administration method, etc., for example, in the case of an injection, it is usually about 0.01 to 3 Omg per day for patients with abnormal lipid metabolism (assuming a body weight of 60 kg).
- the amount can be administered in terms of the weight per 60 kg.
- the protein of the present invention is highly expressed in white adipocytes at the time of high-fat diet load stress, and its expression fluctuates depending on the condition such as diet, stimulation with an insulin resistance regulator, obesity and diabetes, and the like. Since the fluctuation of the expression affects the differentiation of adipocytes, it is considered that they play an important role in the regulation of adipocyte differentiation and metabolic function.
- compounds that alter the binding between the protein of the present invention and its ligand (or receptor) are useful for adipocyte differentiation and metabolism (particularly, It can be used as a prophylactic or therapeutic agent for diseases (such as obesity, diabetes, impaired glucose tolerance, arteriosclerosis, hypertension, hyperlipidemia) related to abnormalities (insufficiency or enhancement of glucose and lipid metabolism). .
- diseases such as obesity, diabetes, impaired glucose tolerance, arteriosclerosis, hypertension, hyperlipidemia
- prophylactic and / or therapeutic agent for a disease associated with dysfunction or enhancement of the protein of the present invention the same as the above-mentioned "prophylactic / therapeutic agent for a disease associated with dysfunction of the protein of the present invention" C
- the preparation obtained in this way is safe and has low toxicity. It can be administered to a substance (eg, human, rat, rabbit, sheep, pig, pig, cat, cat, dog, sal).
- the dose of the compound or a salt thereof varies depending on the administration subject, target organ, symptom, administration method, and the like.
- oral administration in general, for example, in a patient with abnormal glucose / lipid metabolism (with a body weight of 60 kg). Is about 0.1 to 100 mg per day, preferably about 1.0 to 50 mg, more preferably about 1.0 to 20 mg.
- parenteral administration the single dose varies depending on the administration target, target organ, symptoms, administration method, and the like.
- the amount can be administered in terms of the body weight per 60 kg.
- the antibody of the present invention can specifically recognize the protein (peptide) of the present invention, it is used for the quantification of the protein (peptide) of the present invention in a test solution, particularly for quantification by a sandwich immunoassay. can do. That is, the present invention provides, for example, (i) reacting an antibody of the present invention with a test solution and a labeled protein (peptide) of the present invention in a competitive manner, and the labeled protein (peptide) bound to the antibody; A method for quantifying the protein ( ⁇ peptide) of the present invention in a test solution, which comprises measuring the ratio of
- the insolubilized antibody and the labeled antibody have an antigen recognition site that does not hinder the binding to the protein (peptide) of the present invention (for example, one of the antibodies
- the N-terminal of the protein (peptide) of the present invention is recognized, and the other antibody reacts with the C-terminal of the protein (peptide) of the present invention, etc.).
- the protein (peptide) of the present invention can be measured using a monoclonal antibody against the protein (peptide) of the present invention (hereinafter sometimes referred to as the monoclonal antibody of the present invention), and detection by tissue staining or the like can be performed. You can also.
- the antibody molecule itself may be used, or the F (ab ') 2, Fab', or F'ab fraction of the antibody molecule may be used.
- the measurement method using an antibody against the protein (peptide) of the present invention is not particularly limited, and may be an antibody, an antigen or an antibody corresponding to the amount of the antigen in the test solution (for example, the amount of the protein of the present invention). Any method can be used to detect the amount of one antigen complex by chemical or physical means and calculate this from a standard curve prepared using a standard solution containing a known amount of antigen. Is also good.
- nephrometry for example, nephrometry, a competition method, an immunometric method, and a sandwich method are suitably used, but it is particularly preferable to use a sandwich method described later in terms of sensitivity and specificity.
- a labeling agent used in a measurement method using a labeling substance for example, a radioisotope, an enzyme, a fluorescent substance, a luminescent substance and the like are used. Is a radioactive isotope, for example, [1 2 5 I], [1 3 1 I], [3 H], Ru is used and [1 4 C].
- a radioactive isotope for example, [1 2 5 I], [1 3 1 I], [3 H], Ru is used and [1 4 C].
- the above-mentioned enzyme those which are stable and have a large specific activity are preferable.
- fluorescent substance for example, fluorescamine, fluorescein isothiosinate and the like are used.
- luminescent substance for example, luminol, luminol derivative, luciferin, lucigenin and the like are used.
- a biotin-avidin system can be used for binding the antibody or antigen to the labeling agent.
- insolubilization of an antigen or an antibody physical adsorption may be used, or a method using a chemical bond usually used for insolubilizing or immobilizing a protein or an enzyme may be used.
- the carrier for example, insoluble polysaccharides such as agarose, dextran, and cellulose; synthetic resins such as polystyrene, polyacrylamide, and silicon; and glass are used.
- a test solution is reacted with the insolubilized monoclonal antibody of the present invention (primary reaction), and the labeled monoclonal antibody of the present invention is further reacted.
- secondary reaction the amount of the protein of the present invention in the test wave can be determined by measuring the activity of the labeling agent on the insolubilized carrier.
- the primary reaction and the secondary reaction may be performed in the reverse order, may be performed simultaneously, or may be performed at staggered times.
- the labeling agent and the method of insolubilization can be the same as those described above.
- the antibody used for the solid phase antibody or the labeling antibody is not necessarily one kind, and a mixture of two or more kinds of antibodies is used for the purpose of improving the measurement sensitivity and the like. May be used.
- the monoclonal antibody of the present invention used in the primary reaction and the secondary reaction has a site where the protein (peptide) of the present invention binds.
- Different antibodies are preferably used. That is, the antibody used in the primary reaction and the secondary reaction is used in the primary reaction, for example, when the antibody used in the secondary reaction recognizes the C-terminal of the protein (peptide) of the present invention.
- an antibody that recognizes preferably other than the C-terminal for example, an N-terminal is used.
- the monoclonal antibody of the present invention can be used in a measurement system other than the sandwich method, for example, a competition method, an immunometric method, or a nephrometry.
- the competition method after the antigen in the test wave and the labeled antigen are allowed to react competitively with the antibody, the unreacted labeled antigen is separated from (F) and the labeled antigen (B) bound to the antibody ( BZF separation), measure the amount of labeling of either B or F, and quantify the amount of antigen in the test wave.
- a soluble antibody is used as an antibody
- BZF separation is performed using polyethylene glycol
- a liquid phase method using a second antibody against the above antibody or a solid phase antibody is used as the first antibody.
- An immobilization method using an immobilized antibody as the second antibody and a soluble antibody as the second antibody is used.
- an antigen in a test wave and a solid-phased antigen are subjected to a competitive reaction with a fixed amount of a labeled antibody, and then a solid phase and a liquid phase are separated. And an excess amount of the labeled antibody, and then immobilized antigen is added to bind the unreacted labeled antibody to the solid phase, and then the solid phase and the liquid phase are separated. Next, The amount of label in any of the phases is measured to determine the amount of antigen in the test solution.
- nephrometry the amount of insoluble sediment generated as a result of an antigen-antibody reaction in a gel or in a solution is measured. Even when the amount of antigen in the test solution is small and only a small amount of sediment is obtained, laser nephrometry utilizing scattering by a laser is preferably used.
- the measurement system for the protein (peptide) of the present invention may be constructed by adding ordinary technical considerations of those skilled in the art to the ordinary conditions and operation methods in each method. For details of these general technical means, it is possible to refer to reviews and compendiums.
- the protein (peptide) of the present invention can be quantified with high sensitivity by using the antibody of the present invention.
- various diseases associated with dysfunction or enhancement of the protein of the present invention can be diagnosed by quantifying the protein of the present invention or salts thereof in vivo using the antibody of the present invention.
- the protein of the present invention is highly expressed in white adipocytes during a high-fat diet load stress, and The expression of the protein of the present invention varies depending on the disease state such as obesity and diabetes, and the fluctuation of the expression affects the differentiation of adipocytes.
- Diseases associated with abnormalities (insufficiency or enhancement) of adipocyte differentiation and / or metabolic functions (particularly glucose and lipid metabolism) eg, obesity, diabetes, impaired glucose tolerance, arteriosclerosis, hypertension, hyperlipidemia) Disease).
- the antibody of the present invention can be used for specifically detecting the protein of the present invention or a salt thereof present in a subject such as a body fluid or a tissue.
- preparation of an antibody column used for purifying the protein (peptide) of the present invention, detection of the protein (peptide) of the present invention in each fraction at the time of purification, and protein of the present invention in test cells It can be used to analyze the behavior of
- the antibody of the present invention can specifically recognize the protein (peptide) of the present invention, it can be used for screening for a compound that changes the amount of the protein of the present invention in the cell membrane or extracellularly.
- Non-human mammal 1) Blood, 2) Specific organs, 3) Tissues or cells isolated from the organs are destroyed, then the cell membrane fraction is isolated, and the protein of the present invention contained in the cell membrane fraction.
- the present invention provides a method for screening a compound that changes the amount of the protein (peptide) of the present invention in a cell membrane by confirming the protein (peptide) of the present invention on the cell membrane.
- the quantification of the protein (peptide) of the present invention contained in the cell membrane fraction is specifically performed as follows.
- non-human mammals e.g., mice, rats, egrets, higgs, bushus, puppies, cats, dogs, monkeys, etc.
- Drugs for example, anti-obesity drugs, anti-diabetic drugs, antihypertensive drugs, vasoactive drugs, anti-cancer drugs, etc.
- physical stress for example, flooding stress, electricity
- tissues e.g, brown or white adipose tissue
- Obtain cells eg, fat cells, muscle cells, etc.
- the obtained cells and the like are suspended in, for example, an appropriate buffer (for example, a Tris-chloride buffer, a phosphate buffer, a HEPES buffer, or the like), and a surfactant (for example, Triton X100 TM , by using a Tween, such as 2 0 TM) destroy Said sub ⁇ , the cell membrane fraction is obtained using further centrifugation or filtration, a technique such as column fractionation.
- an appropriate buffer for example, a Tris-chloride buffer, a phosphate buffer, a HEPES buffer, or the like
- a surfactant for example, Triton X100 TM , by using a Tween, such as 2 0 TM
- the cell membrane fraction refers to a fraction abundant in cell membrane obtained by disrupting cells and then obtained by a method known per se.
- Cell disruption methods include Potter— Methods such as crushing cells with an Elvehjem homogenizer, crushing with a Perling blender or Polytron (manufactured by Kinematica), crushing by ultrasonic waves, crushing by blowing cells from a thin nozzle while applying pressure by French press, etc. No.
- the fractionation by centrifugal force such as fractionation centrifugation or density gradient centrifugation is mainly used for fractionation of cell membrane.
- the membrane fraction is rich in the protein (peptide) of the present invention and membrane components such as cell-derived phospholipids and membrane proteins.
- the protein (peptide) of the present invention contained in the cell membrane fraction can be quantified by, for example, sandwich immunoassay using the antibody of the present invention, Western blot analysis, or the like.
- Such a sandwich immunoassay can be performed in the same manner as described above, and the Western plot can be performed by a means known per se.
- a transformant expressing the protein (peptide) of the present invention is prepared according to the method described above, and the protein (peptide) of the present invention contained in the cell membrane fraction can be quantified.
- Screening for a compound that alters the amount of the protein of the present invention in the cell membrane comprises:
- test compound is administered, and after a lapse of a certain period of time after administration (3'0 minutes to 3 days, preferably 1 hour to 2 days, more preferably 1 hour to 24 hours), the protein of the present invention in the cell membrane.
- the test compound is mixed in the medium, and after culturing for a certain period of time (1 to 7 days, preferably 1 to 3 days, more preferably 2 days to After 3 days), the determination can be performed by quantifying the amount of the protein (peptide) of the present invention in the cell membrane.
- non-human mammals e.g., mice, rats, egrets, higgs, bushus, puppies, cats, dogs, monkeys, etc .; more specifically, obese mice, diabetic mice, hypertension
- Drugs eg, antiobesity drugs, antidiabetic drugs, antihypertensive drugs, vasoactive drugs, anticancer drugs, etc.
- physical stress e.g, flooding stress, electric shock
- Blood or specific organs (eg, liver, kidney, etc.), tissues (eg, brown or white adipose tissue) or cells (eg, fat) Cells).
- the obtained cells and the like are cut into tissue sections according to a conventional method, and immunostaining is performed using the antibody of the present invention.
- the protein of the present invention on the cell membrane can be quantitatively or qualitatively confirmed by confirming the protein of the present invention on the cell membrane. You can check the quantity.
- a kit for screening a compound that changes the amount of the protein of the present invention in a cell membrane is characterized by containing the antibody of the present invention as a component.
- the antibody of the present invention can be provided in any of the forms described in (10) above, depending on the immunological assay method to be used.
- the antibody of the present invention used in the primary reaction may be a suitable insoluble carrier (eg, synthetic resins such as insoluble polysaccharides such as agarose, dextran, and cellulose, polystyrene, polyacrylamide, and silicon).
- the antibody of the present invention used for the secondary reaction in a state of being (or possibly being) fixed to
- radioisotopes [1 2 5 I], [1 3 1 I], [3 H], etc. [1 4 C]
- Enzymes (3-galactosidase,) 3-darcosidase, alkaline phosphatase, peroxidase, malate dehydrogenase, etc., fluorescent substances (fluorescamine, fluorescein isothiosinate, etc.), luminescent substances ( Luminol, luminol derivatives, luciferin, lucigenin, etc.).
- the screening kit may further comprise, if desired, a blocking reagent or a washing solution necessary or suitable for immunological measurement, a reagent or a suitable reagent for isolating a cell membrane fraction, a protein of the present invention ( And a transformant that expresses the peptide).
- the screening method and the screening kit described above specifically described screening for a compound that alters the amount of the protein of the present invention in a cell membrane when the protein of the present invention is a membrane protein, those skilled in the art It goes without saying that the above method can be easily applied to screening for a compound that changes the amount of the protein of the present invention outside the cell when the protein of the present invention is a secretory protein. Absent.
- the compound or a salt thereof obtained by using the above screening method is a compound having an action of changing the amount of the membrane protein of the present invention in the cell membrane or the amount of the secretory protein of the present invention extracellularly.
- the cell stimulating activity through ligand-receptor interaction eg, arachidonic acid release, acetylcholine release, Intracellular Ca 2+ release, Intracellular CAMP production, Intracellular cGMP production, Inositol phosphate production, Cell membrane potential fluctuation, Intracellular protein phosphorylation, Activation of c-fos, Low pH Compound that enhances or suppresses the activity of
- (Mouth) A compound that reduces the cell stimulating activity by reducing the amount of the membrane protein of the present invention in the cell membrane or the amount of the secretory protein of the present invention outside the cell.
- Examples of the compound include peptides, proteins, non-peptidic compounds, synthetic compounds, and fermentation products. These compounds may be novel compounds, Known compounds may be used.
- the compound that enhances the cell stimulating activity is useful as a safe and low-toxic drug for enhancing the physiological activity of the protein of the present invention.
- the compound that attenuates the cell stimulating activity is useful as a safe and low toxic drug for decreasing the physiological activity of the protein of the present invention.
- a compound or a salt thereof obtained by the above-mentioned screening method is used as a medicament, it can be formulated as in the above-mentioned "agent for preventing / treating a disease associated with dysfunction of the protein of the present invention".
- the preparations obtained in this way are safe and have low toxicity, so they can be administered to mammals (eg humans, rats, puppies, sheep, pigs, puppies, cats, dogs, sal, etc.) can do.
- mammals eg humans, rats, puppies, sheep, pigs, puppies, cats, dogs, sal, etc.
- the dose of the compound or a salt thereof varies depending on the administration subject, target organ, symptom, administration method, and the like.
- oral administration in general, for example, in a patient with abnormal glucose / lipid metabolism (with a body weight of 60 kg). Is about 0.1 to 100 mg per day, preferably about 1.0 to 5 Omg, more preferably about 1.0 to 20 mg.
- parenteral administration the single dose varies depending on the administration target, target organ, symptoms, administration method, and the like.
- the dose can be administered in terms of the weight per 60 kg of body weight.
- the protein of the present invention is highly expressed in white adipocytes during high-fat diet load stress, and its expression fluctuates depending on the diet, stimulation with an insulin resistance regulator, obesity and diabetes, and the like. Since the fluctuation of the expression affects the differentiation of adipocytes, it is considered that they play an important role in adipocyte differentiation and regulation of Z or metabolic function. Therefore, in the cell membrane or extracellular Compounds that alter the amount of the protein of the present invention include diseases associated with abnormalities (insufficiency or enhancement) in adipocyte differentiation and / or metabolic functions (especially sugar / lipid metabolism) (eg, obesity, diabetes, It can be used as a preventive or therapeutic agent for impaired glucose tolerance, arteriosclerosis, hypertension, hyperlipidemia, etc.
- diseases associated with abnormalities insufficiency or enhancement
- metabolic functions especially sugar / lipid metabolism
- the compound When the compound is used as a prophylactic / therapeutic agent for a disease associated with dysfunction or enhancement of the protein of the present invention, the compound is used in the same manner as in the above-mentioned "prophylactic / therapeutic agent for a disease associated with the dysfunction of the protein of the present invention". Can be formulated.
- the preparations obtained in this way are safe and low toxic, so they can be used, for example, in mammals (eg, humans, rats, puppies, sheep, bush ', puppies, cats, dogs, sal). Can be administered.
- mammals eg, humans, rats, puppies, sheep, bush ', puppies, cats, dogs, sal.
- the dose of the compound or a salt thereof varies depending on the administration subject, target organ, symptom, administration method, and the like.
- oral administration in general, for example, in a patient with abnormal glucose / lipid metabolism (with a body weight of 60 kg). Is about 0.1-100 mg, preferably about 1.0-5 Omg, more preferably about 1.0-20 mg per day.
- parenteral administration the single dose varies depending on the administration target, target organ, symptoms, administration method, etc. (As 6 O kg), it is convenient to administer about 0.01 to 30 mg per day, preferably about 0.1 to 2 Omg, and more preferably about 0.1 to 1 Omg per day. .
- the dose can be administered in terms of the weight per 60 kg of body weight.
- the present invention has a DNA encoding the exogenous protein of the present invention (hereinafter abbreviated as the exogenous DNA of the present invention) or a mutant DNA thereof (sometimes abbreviated as the exogenous mutant DNA of the present invention).
- the exogenous DNA of the present invention or a mutant DNA thereof (sometimes abbreviated as the exogenous mutant DNA of the present invention).
- a non-human mammal is provided.
- Non-human mammals having the exogenous DNA of the present invention or the mutant DNA thereof include unfertilized eggs, fertilized eggs, spermatozoa and their progenitor cells.
- the DNA transgenic animal of the present invention include unfertilized eggs, fertilized eggs, spermatozoa and their progenitor cells.
- the stage of embryonic development in non-human mammal development preferably, at the stage of single cells or fertilized egg cells and generally before the 8-cell stage
- calcium phosphate method preferably, at the stage of single cells or fertilized egg cells and generally before the 8-cell stage
- calcium phosphate method preferably, at the stage of single cells or fertilized egg cells and generally before the 8-cell stage
- electric pulse method preferably, Lipofection It can be produced by transferring the target DNA by a method such as a coagulation method, a coagulation method, a microinjection method, a particle gun method, or a DEAE-dextran method.
- the exogenous DNA of the present invention can be transferred to body cells, organs of living organisms, tissue cells, and the like by the DNA transfer method, and can be used for cell culture, tissue culture, and the like. Can be fused with the above-mentioned germ cells by a cell fusion method known per se to produce the DNA-transferred animal of the present invention.
- non-human mammal for example, red sea lions, bushes, higgins, goats, blue herons, dogs, cats, guinea pigs, hamsters, mice, rats, and the like are used.
- rodents are relatively short in terms of ontogeny and biological cycle in terms of the creation of diseased animal model systems, and rodents that are easy to breed, especially mice (for example, hybrids such as C57BLZ6 and DBA2 as pure strains)
- a strain a B6C strain, a BDFi strain, a B6D2F strain, a BALBZc strain, an ICR strain, etc.
- a rat eg, Wistar, SD, etc.
- mammals in a recombinant vector that can be expressed in mammals include humans and the like in addition to the above-mentioned non-human mammals.
- the exogenous DNA of the present invention refers to the DNA of the present invention once isolated and extracted from a mammal, not the DNA of the present invention originally possessed by a non-human mammal.
- mutant DNA of the present invention those in which a mutation (for example, mutation) has occurred in the nucleotide sequence of the original DNA of the present invention, specifically, addition, deletion, DNA that has been replaced with a base or the like is used, and also includes abnormal DNA.
- a mutation for example, mutation
- the abnormal DNA means a DNA that expresses an abnormal protein or the like of the present invention, such as DNA that expresses a protein or the like that suppresses the function of the normal protein of the present invention.
- the exogenous DNA of the present invention may be derived from a mammal of the same species or a different species as the target animal.
- a promoter capable of being expressed in animal cells For example, when the human DNA of the present invention is transferred, it may be derived from various mammals (eg, egret, dog, cat, guinea pig, hampus, rat, mouse, etc.) having the DNA of the present invention having high homology thereto.
- a DNA construct eg, a vector, etc.
- a DNA construct comprising the human DNA of the present invention downstream of various promoters capable of expressing DNA into a fertilized egg of a target mammal, for example, a mouse fertilized egg;
- a DNA-transferred mammal that highly expresses the DNA of the present invention can be produced.
- Examples of the expression vector for carrying the DNA of the present invention include a plasmid derived from Escherichia coli, a plasmid derived from Bacillus subtilis, a plasmid derived from yeast, a bacteriophage such as ⁇ phage, a retrovirus such as Moroni monoleukemia virus, a vaccinia virus or Animal viruses such as baculovirus are used.
- a plasmid derived from Escherichia coli, a plasmid derived from Bacillus subtilis or a plasmid derived from yeast are preferably used.
- promoters that regulate DNA expression include, but are not limited to: (1) DNA derived from viruses (eg, Simian virus, cytomegalovirus, Moroni mouse leukemia virus, JC virus, breast cancer virus, poliovirus, etc.) Promoters 2 Promoters derived from various mammals (human, egret, dog, cat, guinea pig, hamster, rat, mouse, etc.), for example, albumin, insulin II, peroplatin II, elastase, erythrocyte poetin, endothelin, muscle Creatine kinase, glial fibrillary acidic protein, Daltathione S-transferase, platelet-derived growth factor / 3, keratin 1, K10 and K14, collagen type I and type II, cyclic AMP-dependent protein kinase / 3 I subunit, dystrophin, tartrate-resistant Lucariphosphatase, atrial natriuretic factor, endothelial receptor thymic
- cytomegalovirus promoter capable of high expression throughout the whole body
- a human peptide chain elongation factor la (EF-1 ⁇ ) promoter a human and a chicken i3 actin promoter are preferable.
- the vector preferably has a sequence that terminates the transcription of the messenger RNA of interest in a DNA-transferred mammal (generally referred to as “Yuichi Mineta”).
- the sequence of A can be used, and preferably, Simian virus SV40 or the like is used.
- a splicing signal of each DNA, an enhancer region, a part of an intron of eukaryotic DNA, etc. are 5 'upstream of the promoter region, between the promoter region and the translation region. Alternatively, it may be linked to the 3 'downstream of the translation region depending on the purpose.
- the normal translation region of the protein or the like of the present invention is derived from liver, kidney, thyroid cells, fibroblasts derived from various mammals (eg, human, rabbit, dog, cat, guinea pig, hamster, rat, mouse, etc.). DNA and various commercially available genomes D From the NA library, it is possible to obtain the whole or a part of the genomic DNA, or the complementary DNA prepared by a known method from RNA derived from liver, kidney, thyroid cells and fibroblasts as a raw material.
- an exogenous abnormal DNA can be obtained by preparing a translation region obtained by mutating a normal translation region of the protein of the present invention or the like obtained from the above cells or tissues by a point mutagenesis method.
- the translation region can be prepared as a DNA construct that can be expressed in a transgenic animal by a conventional DNA engineering technique in which it is connected to the downstream of the promoter (and optionally to the upstream of the transcription termination site).
- Transfer of the exogenous DNA of the present invention at the fertilized egg cell stage is ensured to be present in all germ cells and somatic cells of the target mammal.
- the presence of the exogenous DNA of the present invention in the germinal cells of the produced animal after DNA transfer indicates that the progeny of the produced animal retains the exogenous DNA of the present invention in all of its germ cells and somatic cells Means to do.
- the offspring of such animals inheriting the exogenous DNA of the present invention have the exogenous DNA of the present invention in all of their germ cells and somatic cells.
- the non-human mammal to which the exogenous normal DNA of the present invention has been transferred is confirmed to stably maintain the exogenous DNA by mating, and is subcultured in a normal breeding environment as the DNA-bearing animal. You can do it.
- Transfer of the exogenous DNA of the present invention at the fertilized egg cell stage is ensured to be present in excess in all germ cells and somatic cells of the target mammal.
- Excessive presence of the exogenous DNA of the present invention in the germinal cells of the produced animal after the DNA transfer indicates that all the offspring of the produced animal contain the exogenous DNA of the present invention in all of its germ cells and somatic cells. Means to have.
- the progeny of this type of animal that has inherited the exogenous DNA of the present invention has an excess of the exogenous DNA of the present invention in all of its germinal and somatic cells.
- the non-human mammal having the normal DNA of the present invention expresses the normal DNA of the present invention at a high level, and eventually enhances the function of the endogenous normal DNA, thereby ultimately causing hyperactivity of the protein of the present invention.
- the mammal into which the exogenous normal DNA of the present invention has been transferred has an increased symptom of the released protein of the present invention, it can be used for a screening test for a therapeutic drug for a disease associated with the protein. .
- the non-human mammal having the exogenous abnormal DNA of the present invention is to be confirmed to stably maintain the exogenous DNA by mating, and to be subcultured as an animal having the DNA in a normal breeding environment. Can be done. Furthermore, the desired foreign DNA can be incorporated into the above-mentioned plasmid and used as a source substance.
- the DNA construct with the promoter can be prepared by ordinary DNA engineering techniques. The transfer of the abnormal DNA of the present invention at the fertilized egg cell stage is ensured to be present in all germ cells and somatic cells of the target mammal.
- the presence of the abnormal DNA of the present invention in the germinal cells of the produced animal after the transfer of the DNA means that all the offspring of the produced animal have the abnormal DNA of the present invention in all of the germ cells and somatic cells.
- the progeny of this type of animal that has inherited the exogenous DNA of the present invention has the abnormal DNA of the present invention in all of its germ cells and somatic cells.
- the abnormal DNA of the present invention is highly expressed, and the function of the endogenous normal DNA is inhibited, so that the function of the protein of the present invention is finally inactivated. It may cause type refractory disease and can be used as a model animal for the disease.
- the abnormal DNA transgenic animal of the present invention it is possible to elucidate the pathological mechanism of the function-inactive refractory of the protein of the present invention and to examine a method for treating this disease.
- the abnormal DNA highly expressing animal of the present invention is useful for inhibiting the function of the normal protein by the abnormal protein of the present invention (dominant negative activity) in the inactive refractory disease of the protein of the present invention. ) Is a model for elucidating. Further, since the mammal into which the foreign abnormal DNA of the present invention has been transferred has an increased symptom of the released abnormal protein of the present invention, it is also used for a therapeutic drug screening test for a functionally inactive refractory disease of the protein of the present invention. It is possible.
- ⁇ ⁇ Isolation and purification of the mutant protein of the present invention and production of its antibody can be considered. Further, using the DNA-transferred animal of the present invention, it is possible to examine clinical symptoms of diseases related to the protein of the present invention, including inactive refractory disease of the protein, and the like. More detailed pathological findings in each organ of the disease model related to the disease can be obtained, which can contribute to the development of a new treatment method and the research and treatment of secondary diseases caused by the disease.
- a therapeutic agent for a disease associated with the protein of the present invention including a functionally inactive refractory disease
- using the DNA-transferred animal of the present invention the above-described test method and quantitative method, etc.
- the method it is possible to provide an effective and rapid screening method for the therapeutic agent for the disease.
- using the DNA-transferred animal of the present invention or the exogenous DNA expression vector of the present invention it is possible to examine and develop a method for treating DNA associated with the protein of the present invention.
- the present invention provides a non-human mammalian embryonic stem cell in which the DNA of the present invention is inactivated, and a non-human mammal deficient in expression of the DNA of the present invention.
- a non-human mammal deficient in expression of the DNA in which the DNA of the present invention is inactivated [7] the DNA is obtained by introducing a reporter gene (eg, a / 3-galactosidase gene derived from Escherichia coli).
- a reporter gene eg, a / 3-galactosidase gene derived from Escherichia coli.
- the non-human mammal according to item (6), wherein the non-human mammal is inactivated, and the reporter gene can be expressed under the control of a promoter for the DNA of the present invention.
- a compound or a salt thereof which comprises administering a test compound to the animal according to (7) and detecting the expression of a reporter gene, which enhances or inhibits the activity of the promoter for DNA of the present invention.
- a screening method The non-human mammalian embryonic stem cells in which the DNA of the present invention has been inactivated are artificially mutating the DNA of the present invention possessed by the non-human mammal, thereby suppressing the expression ability of the DNA, Alternatively, by substantially losing the activity of the protein of the present invention encoded by the DNA, the DNA does not substantially have the ability to express the protein of the present invention (hereinafter referred to as the knockout DNA of the present invention). This is sometimes referred to as a non-human mammalian embryonic stem cell (hereinafter abbreviated as ES cell). As the non-human mammal, the same one as described above is used.
- the method of artificially mutating the DNA of the present invention can be performed, for example, by deleting part or all of the DNA sequence and inserting or substituting another DNA by a genetic technique.
- the knockout DNA of the present invention may be prepared by, for example, shifting the codon reading frame or disrupting the function of the promoter or exon by these mutations.
- Non-human mammalian embryonic stem cells in which the DNA of the present invention has been inactivated include, for example,
- the DNA of the present invention possessed by a non-human mammal to be isolated is isolated and its exon portion is a drug resistance gene typified by a neomycin resistance gene, a hygromycin resistance gene, lacZ ( ⁇ -galactosidase gene), DNA sequence that disrupts exon function by inserting a reporter gene, such as the Nicol acetyltransferase gene), or terminates transcription of the gene in the intron between exons.
- a drug resistance gene typified by a neomycin resistance gene, a hygromycin resistance gene, lacZ ( ⁇ -galactosidase gene), DNA sequence that disrupts exon function by inserting a reporter gene, such as the Nicol acetyltransferase gene), or terminates transcription of the gene in the intron between exons.
- a DNA chain having a DNA sequence constructed so as to disrupt the gene (hereinafter abbreviated as targeting vector 1) is introduced into the chromosome of the animal by, for example, a homologous recombination method.
- Southern hybridization analysis using the DNA sequence on or near the DNA of the invention as a probe or DNA sequence on the targeting vector and the targeting vector The neighboring region other than the DNA of the present invention used for the production of the targeting vector Of the knockout ES cells of the present invention by PCR using the DNA sequence of Can be obtained.
- ES cells from which the DNA of the present invention is inactivated by the homologous recombination method or the like for example, those already established may be used as described above.
- a newly established one may be used.
- 129 ES cells are generally used, but since the immunological background is not clear, an alternative pure immunological and genetically
- BDF mice C57BL / 6 mice and C57B LZ6 that have reduced the number of eggs 08 eight / / 2 and 1) can be favorably used such as that established with.
- BDFi mice have the advantage of high number of eggs collected and robust eggs.
- C57BLZ6 mice are used as a background
- ES cells obtained using these mice have the following characteristics: It can be used advantageously in that the genetic background can be replaced by C57BL6 mice by backcrossing with 57BLZ6 mice.
- blastocysts 3.5 days after fertilization are generally used. Early embryos can be obtained.
- male ES cells are generally more convenient for producing a germline chimera. It is also desirable to discriminate between males and females as soon as possible in order to reduce the complexity of culturing.
- An example of a method for determining the sex of ES cells is a method of amplifying and detecting a gene in the sex-determining region on the Y chromosome by PCR. If this method was used, the number of ES cells required for a karyotype analysis would have been about 10 6 , but only about 1 colony of ES cells (about 50 cells) was required.
- the primary selection of ES cells in the initial stage can be performed by gender discrimination, and the selection of male cells at an early stage can greatly reduce the labor required in the initial stage of culture.
- the secondary selection can be performed, for example, by confirming the number of chromosomes by the G_banding method.
- the number of chromosomes in the resulting ES cells 100% of the normal number is desirable, but if it is difficult due to physical manipulations at the time of establishment, knock out the gene of the ES cell, and It is desirable to clone again into a certain cell).
- Embryonic stem cell lines obtained in this way usually have very good growth potential, but must be carefully subcultured because they tend to lose their ability to develop somatically.
- LIF on a suitable feeder cell such as STO fibroblasts
- the non-human mammal deficient in DNA expression of the present invention can be compared with a normal animal by measuring the mRNA amount of the animal using a known method and indirectly comparing the expression level. It is possible to distinguish.
- non-human mammal the same one as described above is used.
- the non-human mammal deficient in DNA expression of the present invention can be obtained, for example, by introducing the evening-getting vector produced as described above into a mouse embryonic stem cell or a mouse egg cell, and The DNA sequence in which the DNA of the present invention has been inactivated undergoes homologous recombination to replace the DNA of the present invention on the chromosome of a mouse embryonic stem cell or mouse egg cell by gene homologous recombination. Can be knocked out. Since most of the recombination in mammals is non-homologous, means for screening cells that have undergone homologous recombination include, for example, drug resistance such as a neomycin resistance gene inside the DNA of the present invention.
- a drug corresponding to the inserted drug resistance gene is constructed by inserting a gene and constructing a targeting vector containing a thymidine kinase (tk) gene in the vicinity of the DNA of the present invention and introducing the vector into embryonic stem cells or egg cells.
- tk thymidine kinase
- G418 for the neomycin resistance gene
- ganciclovir resistance is obtained. Since it is incorporated at the same time, it has a ganciclovir impression.
- the randomly inserted cells are killed by the production of the toxin, so that selection with a single drug becomes possible.
- the final confirmation of the cells in which the DNA of the present invention was knocked out was performed by Southern hybridization analysis or DNA sequence on the gettering vector using the DNA sequence on or near the DNA of the present invention as a probe.
- the analysis can be performed by PCR using the DNA sequence of the neighboring region other than the DNA of the present invention derived from the mouse used as one targeting vector as a primer.
- non-human mammalian embryonic stem cells When non-human mammalian embryonic stem cells are used, clone the cell line in which the DNA of the present invention has been inactivated by homologous recombination and The chimeric embryo thus prepared is injected into the uterus of the pseudo-pregnant non-human mammal.
- the produced animal is a chimeric animal composed of both cells having the normal DNA locus of the present invention and cells having the artificially mutated DNA locus of the present invention.
- all tissues are artificially mutated from a population obtained by crossing such a chimeric individual with a normal individual. It can be obtained by selecting individuals composed of cells having the added DNA locus of the present invention, for example, by judging coat color or the like. Since individuals obtained in this manner are usually individuals with heterozygous expression deficiency, the individuals with heterozygous expression deficiency can be bred to obtain individuals with homozygous expression deficiency of the protein of the present invention from their offspring. .
- a transgenic non-human mammal having a chromosome into which a gettering vector has been introduced can be obtained by injecting a DNA solution into a nucleus of an egg cell by a microinjection method.
- These transgenic non-human mammals can be obtained by selecting those having a mutation at the DNA locus of the present invention by homologous gene recombination.
- the animal individual obtained by the crossing can confirm that the DNA has been knocked out, and can be reared in a normal breeding environment. .
- the germline can be obtained and maintained according to a conventional method. That is, by crossing male and female animals having the inactivated DNA, a homozygous animal having the inactivated DNA on both homologous chromosomes can be obtained. The obtained homozygous animal can be efficiently obtained by rearing the mother animal in such a manner that one normal individual and a plurality of homozygous animals are obtained. By crossing male and female heterozygous animals, homozygous and heterozygous animals having the inactivated DNA are bred and subcultured.
- the non-human mammalian embryonic stem cells in which the DNA of the present invention has been inactivated are extremely useful for producing the non-human mammal deficient in expression of the DNA of the present invention.
- the non-human mammal deficient in DNA expression of the present invention is The lack of various biological activities that can be induced can serve as a model for diseases caused by inactivation of the biological activity of the protein, and is useful for investigating the causes of these diseases and examining therapeutic methods.
- the non-human mammal deficient in DNA expression of the present invention can be used for screening a compound having a therapeutic / preventive effect against diseases caused by DNA deficiency or damage of the present invention.
- the present invention is characterized in that a test compound is administered to a non-human mammal deficient in expression of a DNA of the present invention, and changes in the animal are observed and measured.
- the present invention provides a method for screening a compound or a salt thereof, which has a therapeutic / preventive effect against a disease that occurs.
- Examples of the non-human mammal deficient in DNA expression of the present invention used in the screening method include the same as described above.
- Test compounds include, for example, peptides, proteins, non-peptidic compounds, synthetic compounds, fermentation products, cell extracts, plant extracts, animal tissue extracts, and plasma, and these compounds are novel compounds. Or a known compound.
- a non-human mammal deficient in expression of the DNA of the present invention is treated with a test compound and compared with an untreated control animal, and changes in organs, tissues, disease symptoms, etc. of the animal are indicated as an index.
- the therapeutic and prophylactic effects of the test compound can be tested.
- a method of treating a test animal with a test compound for example, oral administration, intravenous injection, or the like is used, and an appropriate method is selected according to the symptoms of the test animal, properties of the test compound, and the like.
- the dose of the test compound can be appropriately selected depending on the administration method, the properties of the test compound, and the like.
- the blood glucose level of the test animal is about 10% or more, preferably about 30% or more: more preferably, about 50% or more. Treating the test compound against the above-mentioned diseases It can be selected as a compound having a preventive effect.
- the compound obtained by using the screening method is a compound selected from the test compounds described above, and is a disease caused by deficiency or damage of the protein of the present invention, for example, differentiation and / or metabolism of fat cells. It can be used as a safe and low-toxic treatment or prophylactic agent for diseases associated with abnormal functions (eg, obesity, diabetes, impaired glucose tolerance, arteriosclerosis, hypertension, hyperlipidemia). it can. Furthermore, compounds derived from the compounds obtained by the above screening can be used in the same manner.
- the compound obtained by the screening method may form a salt.
- the salt of the compound include physiologically acceptable acids (eg, inorganic acids, organic acids, etc.) and bases (eg, alkalis). And the like, for example, metals), and physiologically acceptable acid addition salts are particularly preferable.
- salts include salts with inorganic acids (eg, hydrochloric acid, phosphoric acid, hydrobromic acid, sulfuric acid, etc.) and organic acids (eg, acetic acid, formic acid, propionic acid, fumaric acid, maleic acid, etc.) Acid, succinic acid, tartaric acid, citric acid, malic acid, oxalic acid, benzoic acid, methanesulfonic acid, benzenesulfonic acid, etc.).
- inorganic acids eg, hydrochloric acid, phosphoric acid, hydrobromic acid, sulfuric acid, etc.
- organic acids eg, acetic acid, formic acid, propionic acid, fumaric acid, maleic acid, etc.
- Acid succinic acid, tartaric acid, citric acid, malic acid, oxalic acid, benzoic acid, methanesulfonic acid, benzenesulfonic acid, etc.
- a drug containing the compound obtained by the screening method or a salt thereof can be formulated in the same manner as in the above "Preventive / therapeutic agent for diseases associated with dysfunction of the protein of the present invention".
- the preparations obtained in this way are safe and have low toxicity, for example, mammals (eg, humans, rats, mice, guinea pigs, egrets, sheep, sheep, bush dogs, dogs, cats, dogs, monkeys) Etc.).
- the dose of the compound or a salt thereof varies depending on the target disease, the subject of administration, the administration route, and the like.
- the compound is orally administered, for example, patients with abnormal glucose / lipid metabolism (body weight 6 (As 0 kg), from about 0.1 to: L 0 O mg per day, preferably from about 1.0 to 5 O mg, more preferably from about 1.0 to 20 mg per day.
- the single dose varies depending on the subject to be administered, the target organ, symptoms, administration method, etc. 6 O kg) It is convenient to administer about 0.01 to 3 Omg per day, preferably about 0.1 to 20 mg, more preferably about 0.1 to 1 Omg per day. Even when a subject to be administered is an animal other than a human, the dose can be administered in terms of the body weight per 6 O kg.
- the present invention provides a test compound administered to a non-human mammal deficient in expression of a DNA of the present invention, and detects or promotes the activity of a promoter of the DNA of the present invention, which is characterized by detecting expression of a reporter gene.
- a method for screening a compound or a salt thereof is provided.
- the non-human mammal deficient in expressing DNA of the present invention may be selected from the non-human mammal deficient in expressing DNA of the present invention by introducing the reporter gene into the DNA of the present invention. Those which are activated and which can express the reporter gene under the control of the promoter for the DNA of the present invention are used.
- test compound examples include the same compounds as described above.
- reporter gene the same ones as described above are used; 3-galactosidase gene (1 ac Z), soluble alkaline phosphatase gene or luciferase gene and the like are preferable.
- the protein of the present invention can be simply and in vivo Can be observed. Specifically, a mouse deficient in the protein of the present invention or a tissue section thereof is fixed with daltaraldehyde, washed with phosphate buffered saline (PBS), and then stained with a staining solution containing X-ga1.
- a reagent that becomes a substrate for / 3-galactosidase such as 5_broth_4-chloro-3-indolyl / 3 / 3-galactopyranoside (X-gal).
- the i3-galactosidase reaction is stopped by washing the tissue specimen with lm MED TA / PBS solution, and the color is observed. Good. Further, mRNA encoding lacZ may be detected according to a conventional method.
- the compound or a salt thereof obtained by the above screening method is a compound selected from the test compounds described above, and is a compound that promotes or inhibits the promoter activity of DNA of the present invention.
- the compound obtained by the screening method may form a salt.
- the salt of the compound include physiologically acceptable acids (eg, inorganic acids) and bases (eg, organic acids). And the like, and particularly preferably a physiologically acceptable acid addition salt.
- Such salts include, for example, salts with inorganic acids (eg, hydrochloric acid, phosphoric acid, hydrobromic acid, sulfuric acid, etc.) or organic acids (eg, acetic acid, formic acid, propionic acid, fumaric acid, maleic acid,
- salts with succinic acid, tartaric acid, citric acid, malic acid, oxalic acid, benzoic acid, methanesulfonic acid, benzenesulfonic acid, etc. are used.
- the compound or a salt thereof that promotes the promoter activity of the DNA of the present invention can promote the expression of the protein of the present invention and promote the function of the protein. It is useful as a medicine for preventing and treating remedies.
- the compound of the present invention or a salt thereof that inhibits the promoter activity for DNA can inhibit the expression of the protein of the present invention and inhibit the function of the protein, for example, a disease associated with overexpression of the protein It is useful as a drug such as a preventive or therapeutic drug.
- Diseases associated with dysfunction or overexpression of the protein of the present invention include, for example, diseases involving abnormalities of adipocyte differentiation and / or metabolic function (eg, obesity, diabetes, impaired glucose tolerance, arteriosclerosis). , Hypertension, hyperlipidemia, etc.) No.
- a drug containing the compound or a salt thereof obtained by the screening method can be produced in the same manner as a drug containing a compound that alters the binding property between the protein of the present invention and its ligand (or receptor). it can.
- the preparations obtained in this way are safe and low toxic, and can be used, for example, in mammals (eg, humans, rats, mice, guinea pigs, egrets, higgs, bushus, dogs, dogs, cats, dogs, Monkeys).
- mammals eg, humans, rats, mice, guinea pigs, egrets, higgs, bushus, dogs, dogs, cats, dogs, Monkeys.
- the dose of the compound or a salt thereof varies depending on the target disease, the administration subject, the administration route, and the like.
- a compound that promotes or inhibits the promoter overnight activity against DNA of the present invention is orally administered, Generally, for example, in a patient with a sugar / lipid metabolism disorder (assuming a body weight of 60 kg), about 0.1 to 10 Omg, preferably about 1.0 to 5 Omg, more preferably about 1.0 to 20 mg per day It is.
- the single dose varies depending on the administration target, target organ, symptoms, administration method, etc.
- it is usually used, for example, in patients with abnormal glucose and lipid metabolism (body weight).
- the non-human mammal deficient in expression of the DNA of the present invention is extremely useful for screening a compound or its salt that promotes or inhibits the activity of the promoter for the DNA of the present invention, and the expression of the DNA of the present invention. It can greatly contribute to investigating the causes of various diseases caused by insufficiency or developing therapeutic drugs.
- transgenic animal a DNA containing the promoter region of the protein of the present invention
- genes encoding various proteins are ligated downstream thereof and injected into egg cells of an animal to produce a so-called transgenic animal (transgenic animal).
- transgenic animal transgenic animal
- a protein having the action of specifically promoting or suppressing the in vivo production ability of the protein of the present invention itself can be obtained. It can be used as a search system for molecular compounds.
- bases, amino acids, and the like are indicated by abbreviations based on the abbreviations of the IUPAC-IUB Commission on Biochemical Nomenclature or commonly used abbreviations in the art, and examples thereof are described below.
- amino acids can have optical isomers, the L-form is indicated unless otherwise specified.
- FIG. 1 shows the amino acid sequence of mouse white adipose tissue-derived secretory or membrane protein mSSno-14 (Long form).
- FIG. 1 shows the nucleotide sequence of cDNA encoding a secretory or membrane protein mSST20-14 (Short form) derived from mouse white adipose tissue.
- FIG. 2 shows the amino acid sequence of mouse white adipose tissue-derived secretory or membrane protein mSST20-14 (Short form).
- [SEQ ID NO: 5] 1 shows the nucleotide sequence of cDNA encoding secretory or membrane protein mSST22-22 (long form) derived from mouse white adipose tissue.
- FIG. 1 shows the amino acid sequence of mouse white adipose tissue-derived secretory or membrane protein mSST22-22 (Long form).
- FIG. 1 shows the nucleotide sequence of cDNA encoding mouse white adipose tissue-derived secretory or membrane protein mSST-22 (Short form).
- FIG. 2 shows the amino acid sequence of mouse white adipose tissue-derived secretory or membrane protein mSST22-22 (Short form).
- FIG. 1 shows the nucleotide sequence of cDNA encoding mouse white adipose tissue-derived secretory or membrane protein mSST8-5.
- FIG. 2 shows the amino acid sequence of mouse white adipose tissue-derived secretory or membrane protein H1SST8-5.
- FIG. 1 shows the nucleotide sequence of cDNA encoding secretory or membrane protein mSST19-15 (Long form) derived from mouse white adipose tissue.
- FIG. 1 shows the amino acid sequence of mouse white adipose tissue-derived secretory or membrane protein mSST19-15 (Long form).
- FIG. 1 shows the nucleotide sequence of cDNA encoding secretory or membrane protein mSST19-15 (Short form) derived from mouse white adipose tissue.
- FIG. 1 shows the nucleotide sequence of cDNA encoding mouse white adipose tissue-derived secretory or membrane protein mSST13-11.
- FIG. 2 shows the amino acid sequence of mouse white adipose tissue-derived secretory or membrane protein mSST13-11.
- FIG. 1 shows the nucleotide sequence of cDNA encoding mouse white adipose tissue-derived secretory or membrane protein mSST9-8. .
- FIG. 2 shows the amino acid sequence of mouse white adipose tissue-derived secretory or membrane protein mSST9-8.
- FIG. 1 shows the nucleotide sequence of cDNA encoding mouse white adipose tissue-derived secretory or membrane protein mSSni-3.
- FIG. 2 shows the amino acid sequence of mouse white adipose tissue-derived secretory or membrane protein mSST21-3.
- FIG. 1 shows the nucleotide sequence of cDNA encoding mouse white adipose tissue-derived secretory or membrane protein mSST20-6.
- FIG. 2 shows the amino acid sequence of mouse white adipose tissue-derived secretory or membrane protein D1SST20-6.
- FIG. 1 shows the nucleotide sequence of mouse white adipose tissue-derived secretory or membrane protein cDNA fragment mSs 120-14 (partial).
- the nucleotide sequence of 5 (partial) is shown.
- Fig. 3 shows the nucleotide sequence of mouse white adipose tissue-derived secretory or membrane protein cDNA fragment mSstl9-15 (partia1).
- FIG. 1 shows the nucleotide sequence of mouse secretory or membrane protein cDNA fragment InSst9-8 (partial) derived from white adipose tissue.
- FIG. 6 shows the nucleotide sequence of a gene-specific primer for 5′-RACE for identifying the nucleotide sequence encoding the full length of mouse white adipose tissue-derived secretory or membrane protein mSST20-14. [SEQ ID NO: 34]
- 3 shows the nucleotide sequence of a gene-specific primer for 3'-RACE for identifying the nucleotide sequence encoding the full length of mouse white adipose tissue-derived secretory or membrane protein mSSO-14.
- the nucleotide sequence of the gene-specific primer for 5'-RACE for identifying the nucleotide sequence encoding the full length of mouse white adipose tissue-derived secretory or membrane protein mSST22-22 is shown.
- FIG. 3 shows the nucleotide sequence of a 3′-RACE gene-specific primer for identifying the nucleotide sequence encoding the full length of mouse white adipose tissue-derived secretory or membrane protein mSST22-22.
- 5 shows the nucleotide sequence of a gene-specific primer for 5′-RACE for identifying the nucleotide sequence encoding the full length of mouse white adipose tissue-derived secretory or membrane protein mSST8-5.
- 3 shows the nucleotide sequence of a gene-specific primer for 3′-RACE for identifying the nucleotide sequence encoding the full length of mouse white adipose tissue-derived secretory or membrane protein mSST8-5.
- Fig. 4 shows the nucleotide sequence of a gene-specific primer for 5'-RACE for identifying the nucleotide sequence encoding the full length of mouse white adipose tissue-derived secretory or membrane protein H1SST19-15.
- FIG. 3 shows the nucleotide sequence of a gene-specific primer for 3′-RACE for identifying the nucleotide sequence encoding the full length of mouse white adipose tissue-derived secretory or membrane protein mSST 19-15.
- SEQ ID NO: 41 The nucleotide sequence of a gene-specific primer for 5'-RACE for identifying the nucleotide sequence encoding the full length of mouse white adipose tissue-derived secretory or membrane protein mSST13-11 is shown.
- 3 shows the nucleotide sequence of a gene-specific primer for 3′-RACE for identifying the nucleotide sequence encoding the full length of mouse white adipose tissue-derived secretory or membrane protein mSST13-11.
- FIG. 5 shows the nucleotide sequence of a gene-specific primer for 5′-RACE for identifying the nucleotide sequence encoding the full length of mouse white adipose tissue-derived secretory or membrane protein D1SST9-8.
- 3 shows the nucleotide sequence of a gene-specific primer for 3′-RACE for identifying the nucleotide sequence encoding the full length of mouse white adipose tissue-derived secretory or membrane protein mSST9-8.
- the nucleotide sequence of the gene-specific primer for 5'-RACE for identifying the nucleotide sequence encoding the full length of mouse white adipose tissue-derived secretory or membrane protein mSST2-3 is shown.
- 3 shows the nucleotide sequence of a gene-specific primer for 3′-RACE for identifying the nucleotide sequence encoding the full length of mouse white adipose tissue-derived secretory or membrane protein mSST21-3.
- the nucleotide sequence of a gene-specific primer for 5'-RACE for identifying the nucleotide sequence encoding the full length of mouse white adipose tissue-derived secretory or membrane protein mSST20-6 is shown.
- mSST20-6 3 shows the nucleotide sequence of a gene-specific primer for 3'-RACE for identifying the nucleotide sequence to be used.
- Mouse pro B cell line Ba / F3 (RIKEN cell bank; RCB0805) requires IL-3 for its survival and growth. These cells express the thrompopoietin receptor (MPL) on the cell membrane, and form a homodimer by binding of the ligand, thrombopoietin, to transmit a proliferation signal to the cell.
- MPL thrompopoietin receptor
- MPL will become a ligand-independent constitutive Tekikatsu property type (MPL M) by S er 498
- MPL M ligand-independent constitutive Tekikatsu property type
- the extracellular domain to produce a retroviral vector one which is by cormorants design incorporate c DNA 5 'to the MP L M which was deleted, if incorporated cDNA is a signal Sequence the fusion protein encoded protein and MPL M in c DNA is expressed on the cell membrane of B a / F 3, the B AZF 3 is to survive 'grown in IL -3-independent.
- a retroviral vector containing the coding region of Me t 1 ⁇ Th MPL M with the r 441 deleted (AMPL M) (pMX-SST ; Kojima and Kitamura, above) to the BstXI site of a high
- a retrovirus expression library was constructed by inserting cDNA derived from adipose tissue-fat-loaded mouse white adipose tissue, and cloning of secretory membrane protein cDNA was performed.
- mice loaded with high fat diet C57B1 / 6J, 12 weeks old, 30% high fat for 12 days Visceral adipose tissue (white fat around the mesentery and epididymis) was removed from the hamster, and poly A (+) A was isolated using the Quick Prep mRNA Purification Kit (Pharmacia) according to the attached protocol. Isolate and Superscript Choice
- CDNA was converted to cDNA by random hexamer using System (Gibco-BRL).
- the resulting cDNA was inserted into BstXI sites
- Bok retroviral vectors PMX- SST with BstXI adapters one (Invitrogen) was the cDNA 5 'to the MPL M is Raige one Chillon.
- the obtained DNA was introduced into E. coli DH10B strain by electroporation and amplified. Purification of plasmid DNA according to a conventional method, and packaging cells for retrovirus production (Plat-E; Morita et al., Gene Ther., 7 (12): 1063-1066, 2000; entered by Dr.
- coli strains have accession numbers of FERM BP-8106, FERM BP-8109, FERM BP-8105, FERM BP-8107, FERM BP-8108, FERM BP-8104, FERM BP-8102 and FERM BP-8110, respectively. It was deposited on July 2, 2002 at the National Institute of Advanced Industrial Science and Technology (AIST) at the Patent Organism Depositary Center (Tokuto, Tsukuba, Ibaraki Prefecture, 305-8566, Japan).
- AIST National Institute of Advanced Industrial Science and Technology
- Example 1 Using the novel cDNA obtained in Example 1 as a probe, the state of expression of these genes was examined by Northern blot analysis under various conditions.
- the expression level of Sstl3-11 increased in high-fat and high-sucrose-loaded mice compared to control mice. In obesity model mice ob / ob, the expression level was also higher than in control C57bl6 / J mice.
- Sst21-3 The expression level of Sst21-3 was increased in the diabetic model mouse db / db compared to the control C57bl6 / J mouse. In addition, when the expression in 3T3-L1 cells capable of differentiating into white fat was examined, Ss121-3 was also expressed in undifferentiated preadipocytes. Sst20- had a motif capable of binding to lipoprotein lipid in the obtained clone fragment.
- the 5′-RACE gene-specific primer (GSP1) and the 3′-RACE gene Specific primers (GSP2) SEQ ID NOS: 33 and 34 for Sst20-14; SEQ ID NOs: 35 and 36 for Sst22-22, respectively; SEQ ID NOs: 37 and 38 for Sst8-5; Sstl9 SEQ ID NOs: 39 and 40 for -15; SEQ ID NOs: 41 and 42 for Sstl3-ll; SEQ ID NOs: 43 and 44 for Sst9-8; SEQ ID NOs: 45 and 46 for Sst2-3, respectively For Sst20-6, SEQ ID Nos.
- the PCR product was separated by agarose gel electrophoresis, the resulting band was excised from the gel, extracted, and then TA-cloned into PCR4-T0P0 or pENTR / D-TOPO (both from Invitrogen).
- Escherichia coli Topi 0 / pCR4-TOPO SST22-22 long form
- Escherichia coli ToplO / pCR4-TOPO SST22-22 short form
- Escherichia coli Topl0 / pENTR / D-T0P0 SST9-8 (10) Escherichia coli ToplO / pCR4-T0P0 (SST2U3) and (11) Escherichia coli ToplO / pCR4-TOP0 (SST20-6) strain were obtained.
- coli strains are FERM BP-8406, FERM BP-8407, FERM BP-8408, FERM BP-8409, FERM BP-8402, FERM BP-8404, FERM BP-8405, FERM BP-8403, FERM BP- 841K FERM BP-8413 and FERM BP-8412 are provided with accession numbers.
- (1) to (8) are dated June 20, 2003, and (9) to (11) are It has been deposited with the National Institute of Advanced Industrial Science and Technology (AIST) at the Patent Organism Depositary (T305-8566, 1-1 1-1 Tsukuba-Higashi, Ibaraki Prefecture) on June 24, 2003.
- AIST National Institute of Advanced Industrial Science and Technology
- 3T3-L1 cells are seeded on a 6-well plate at a cell count of 2xl0 5 cells / well, and cultured in DMEM (invitrogen) medium supplemented with 10% fetal serum (Invitrogen) at 37 “C for 7 days, and then cultured The solution was aspirated, washed twice with PBS (Invitrogen), and 0 PTI-MEM (Invitrogen) was added at 2 ml / well. 0 PTI-MEM (100 1) and FuGENE TM 6 (10; ti 1, Roche) were added.
- an expression construct pCMV was prepared by inserting SST20-14 (Long form) cDNA into the EcoRI-Hindi II cloning site of the expression plasmid pCMV-Tag4A (Sigma). -2 ⁇ g of SST20-14 was added and left at room temperature for 45 minutes. The expression construct-containing solution was added to the above 3T3-L1 cells, cultured at 37 ° C for 6 hours, and then cultured in DMEM medium supplemented with 10% fetal calf serum under 37 for 40 hours.
- DMEM medium containing 250 nM dexamethasone (Sigma), 0.5 mM 1-methyl-3-isobutylxanthine (Wako Pure Chemical Industries, Ltd.), 10 g / ml insulin (Sigma), and 10% fetal serum serum]. And cultured for 72 hours. Thereafter, the cells were further cultured in DMEM medium supplemented with 10% fetal bovine serum for 8 days. After completion of the culture, the culture solution was aspirated, washed twice with PBS, added with 2 ml of 10 formalin (Wako Pure Chemical), and allowed to stand for 30 minutes. After washing once with distilled water, an oil red-0 solution was added and staining was performed for 10 minutes.
- DMEM medium containing 250 nM dexamethasone (Sigma), 0.5 mM 1-methyl-3-isobutylxanthine (Wako Pure Chemical Industries, Ltd.), 10 g / ml insulin (Sigma), and 10% fetal serum serum.
- 3T3-L1 cells were seeded on a 6-well plate at a cell number of 4xl0 5 cells / well, cultured in DMEM (Invitrogen) medium supplemented with 10 ⁇ fetal serum (Invitrogen) for 5 days under 37 days, and then differentiation medium [250 nM Dexamethasone (Sigma), 0.5 mM trimethyl-3-isobutylxanthine (Wako Pure Chemical Industries, Ltd.), 10 g / ml insulin (Sigma), and 10% fetal serum serum-added DMEM medium], and the cells were further cultured for 24 hours.
- DMEM Invitrogen
- differentiation medium 250 nM Dexamethasone (Sigma), 0.5 mM trimethyl-3-isobutylxanthine (Wako Pure Chemical Industries, Ltd.), 10 g / ml insulin (Sigma), and 10% fetal serum serum-added DMEM medium
- TNF- Gene Techne
- 3T3-L1 cells were seeded in a 6-well plate at a cell count of 4xl0 5 cells / well, and cultured in DMEM (Invitrogen) medium supplemented with 10% fetal calf serum (Invitrogen) at 37 ° C for 5 days to differentiate.
- the medium was replaced with a DMEM medium containing 250 nM dexamethasone (Sigma), 0.5 mM trimethyl-3-isobutylxanthine (Wako Pure Chemical Industries, Ltd.), lO ⁇ g / ml insulin (Sigma), and 10% fetal serum.
- the insulin resistance-improving drug piodarisuzone (10 M, Takeda Pharmaceutical) was added, and the cells were cultured for 72 hours in the presence of insulin. After completion of the culture, the cells were washed with PBS (Invitrogen), and the cells were collected. Total RNA was collected from the collected cells using RNAeasy kit (Qiagen) according to the procedure attached to the kit. Using the collected total RNA, the mRNA expression levels of SST8-5 and 36B4 used as an internal standard were quantified using TaqMan PCR (Applied Biosystems). As a result, the expression level of SST8-5 was increased about 2.4 times as much as that of the control (without addition of Piodari evening hydrochloride) by the addition of Piodari evening hydrochloride. Industrial applicability
- the protein of the present invention is a secretory or membrane protein expressed in white adipocytes upon a high fat diet load, it can be used as a preventive or therapeutic agent for diseases associated with adipocyte differentiation or abnormal metabolic function, or It has an excellent effect as a tool for screening candidate drug compounds that are effective for the prevention and treatment of the disease. Sequence listing free text
- Oligonucleotides designed to function as primers for amplifying mouse white adipocyte-derived secretory or membrane protein cDNA fragments.
- Oligonucleotides designed to function as gene-specific primers for 5'-RACE for identifying the nucleotide sequence encoding the full length of mSST20-14. [SEQ ID NO: 34]
- oligonucleotide designed to function as a gene-specific primer for 3'-RACE for identifying the nucleotide sequence encoding the full length of mSST20-14. [SEQ ID NO: 35]
- Oligonucleotides designed to function as gene-specific primers for 5'-RACE for identifying the nucleotide sequence encoding the full length of mSST22-22. [SEQ ID NO: 36]
- Oligonucleotides designed to function as gene-specific primers for 3'-RACE for identifying the nucleotide sequence encoding the full length of mSST22-22. [SEQ ID NO: 37]
- Oligonucleotide designed to function as a gene-specific primer for 5'-RACE for identifying a nucleotide sequence encoding the full length of mSST8-5.
- Oligonucleotide designed to function as a 3′-RACE gene-specific primer for identifying the nucleotide sequence encoding the full length of mSST8-5.
- Oligonucleotides designed to function as gene-specific primers for 5'-RACE for identifying the nucleotide sequence encoding the full length of mSST19-15. [SEQ ID NO: 40]
- oligonucleotide designed to function as a gene-specific primer for 3'-RACE for identifying a nucleotide sequence encoding the full length of mSST19-15.
- [SEQ ID NO: 41] An oligonucleotide designed to function as a gene-specific primer for 5'-RACE for identifying a full-length nucleotide sequence encoding mSST13-ll.
- Oligonucleotides designed to function as gene-specific primers for 3'-RACE for identifying the full-length nucleotide sequence encoding mSST13-ll. [SEQ ID NO: 43]
- Oligonucleotides designed to function as 5'-RACE gene-specific primers for identifying the full-length nucleotide sequence encoding mSST9-8.
- Oligonucleotide designed to function as a 3′-RACE gene-specific primer for identifying the nucleotide sequence encoding the full length of mSST9-8.
- Oligonucleotides designed to function as gene-specific primers for 3'-RACE for identifying the nucleotide sequence encoding the full length of mSST21-3.
- Oligonucleotides designed to function as gene-specific primers for 5'-RACE for identifying the nucleotide sequence encoding the full length of mSST20-6. [SEQ ID NO: 48]
- Oligonucleotides designed to function as gene-specific primers for 3'-RACE for identifying the nucleotide sequence encoding the full length of mSST20-6.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2003280992A AU2003280992A1 (en) | 2002-07-10 | 2003-07-09 | Novel proteins and use thereof |
EP03741288A EP1541677A4 (en) | 2002-07-10 | 2003-07-09 | NEW PROTEINS AND USE THEREOF |
US10/520,783 US20060110384A1 (en) | 2002-07-10 | 2003-07-09 | Novel proteins and use thereof |
US12/371,525 US7833972B2 (en) | 2002-07-10 | 2009-02-13 | Proteins and use thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002201856 | 2002-07-10 | ||
JP2002-201856 | 2002-07-10 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10520783 A-371-Of-International | 2003-07-09 | ||
US12/371,525 Division US7833972B2 (en) | 2002-07-10 | 2009-02-13 | Proteins and use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004007711A1 true WO2004007711A1 (ja) | 2004-01-22 |
Family
ID=30112593
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2003/008690 WO2004007711A1 (ja) | 2002-07-10 | 2003-07-09 | 新規蛋白質およびその用途 |
Country Status (5)
Country | Link |
---|---|
US (2) | US20060110384A1 (ja) |
EP (1) | EP1541677A4 (ja) |
JP (1) | JP2008173122A (ja) |
AU (1) | AU2003280992A1 (ja) |
WO (1) | WO2004007711A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7638270B2 (en) | 2003-01-24 | 2009-12-29 | Agensys, Inc. | Nucleic acids and corresponding proteins entitled 254P1D6B useful in treatment and detection of cancer |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110104666A1 (en) * | 2009-11-02 | 2011-05-05 | Toshiya Matsubara | Insulin resistance marker |
JP7311620B2 (ja) | 2019-03-08 | 2023-07-19 | メビオン・メディカル・システムズ・インコーポレーテッド | 粒子線治療システムのためのコリメータおよびエネルギーデグレーダ |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000053758A2 (en) * | 1999-03-08 | 2000-09-14 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
WO2001000638A2 (en) * | 1999-06-29 | 2001-01-04 | Millennium Pharmaceuticals, Inc. | Novel genes encoding proteins having diagnostic, preventive, therapeutic, and other uses |
WO2001048192A1 (en) * | 1999-12-23 | 2001-07-05 | Genesis Research & Development Corporation Limited | Polynucleotides, polypeptides expressed by the polynucleotides and methods for their use |
WO2001051636A2 (en) * | 2000-01-14 | 2001-07-19 | Incyte Genomics, Inc. | Secreted proteins |
WO2001053312A1 (en) * | 1999-12-23 | 2001-07-26 | Hyseq, Inc. | Novel nucleic acids and polypeptides |
WO2001057188A2 (en) * | 2000-02-03 | 2001-08-09 | Hyseq, Inc. | Novel nucleic acids and polypeptides |
WO2001064835A2 (en) * | 2000-02-28 | 2001-09-07 | Hyseq, Inc. | Novel nucleic acids and polypeptides |
WO2001090357A1 (en) * | 2000-05-24 | 2001-11-29 | Genesis Research & Development Corporation Limited | Compositions isolated from skin cells and methods for their use |
WO2002022886A2 (en) | 2000-09-18 | 2002-03-21 | Wisconsin Alumni Research Foundation | Expression of genes in diabetes mellitus and insulin resistance |
US20030032155A1 (en) * | 1997-03-31 | 2003-02-13 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE447583T1 (de) | 1997-09-17 | 2009-11-15 | Genentech Inc | Polypeptide und dafür kodierende nukleinsäure |
US20030040471A1 (en) * | 1998-04-29 | 2003-02-27 | Watson James D. | Compositions isolated from skin cells and methods for their use |
AU2001250932A1 (en) * | 2000-03-23 | 2001-10-03 | Diadexus, Inc. | Compositions and methods of diagnosing, monitoring, staging, imaging and treating prostate cancer |
US20020197679A1 (en) * | 2000-06-20 | 2002-12-26 | Tang Y. Tom | Novel nucleic acids and polypeptides |
-
2003
- 2003-07-09 EP EP03741288A patent/EP1541677A4/en active Pending
- 2003-07-09 AU AU2003280992A patent/AU2003280992A1/en not_active Abandoned
- 2003-07-09 WO PCT/JP2003/008690 patent/WO2004007711A1/ja active Application Filing
- 2003-07-09 US US10/520,783 patent/US20060110384A1/en not_active Abandoned
-
2007
- 2007-12-28 JP JP2007338577A patent/JP2008173122A/ja active Pending
-
2009
- 2009-02-13 US US12/371,525 patent/US7833972B2/en not_active Expired - Fee Related
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030032155A1 (en) * | 1997-03-31 | 2003-02-13 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
WO2000053758A2 (en) * | 1999-03-08 | 2000-09-14 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
WO2001000638A2 (en) * | 1999-06-29 | 2001-01-04 | Millennium Pharmaceuticals, Inc. | Novel genes encoding proteins having diagnostic, preventive, therapeutic, and other uses |
WO2001048192A1 (en) * | 1999-12-23 | 2001-07-05 | Genesis Research & Development Corporation Limited | Polynucleotides, polypeptides expressed by the polynucleotides and methods for their use |
WO2001053312A1 (en) * | 1999-12-23 | 2001-07-26 | Hyseq, Inc. | Novel nucleic acids and polypeptides |
WO2001051636A2 (en) * | 2000-01-14 | 2001-07-19 | Incyte Genomics, Inc. | Secreted proteins |
WO2001057188A2 (en) * | 2000-02-03 | 2001-08-09 | Hyseq, Inc. | Novel nucleic acids and polypeptides |
WO2001064835A2 (en) * | 2000-02-28 | 2001-09-07 | Hyseq, Inc. | Novel nucleic acids and polypeptides |
WO2001090357A1 (en) * | 2000-05-24 | 2001-11-29 | Genesis Research & Development Corporation Limited | Compositions isolated from skin cells and methods for their use |
WO2002022886A2 (en) | 2000-09-18 | 2002-03-21 | Wisconsin Alumni Research Foundation | Expression of genes in diabetes mellitus and insulin resistance |
Non-Patent Citations (44)
Title |
---|
"Immune-chemical Techniques", vol. 84, ACADEMIC PRESS PUBLISHING |
"Immunochemical Techniques", ACADEMIC PRESS PUBLISHING |
"Immunochemical Techniques", vol. 121, ACADEMIC PRESS PUBLISHING |
"Immunochemical Techniques", vol. 74, ACADEMIC PRESS PUBLISHING |
"Irnmunochemical Techniques", vol. 92, ACADEMIC PRESS PUBLISHING |
"Radioimmunoassay", 1974, KODANSHA LTD. |
"Sequel to the Radioimmunoassay", 1979, KODANSHA LTD. |
ARITA, Y. ET AL., BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (BIOCHEM. BIOPHYS. RES. COMMUN., vol. 257, no. 1, 1999, pages 79 - 83 |
DATABASE GENBANK [online] 1 February 2002 (2002-02-01), Database accession no. (BC022616) * |
DATABASE GENBANK [online] 1 March 2002 (2002-03-01), Database accession no. (BC024888) * |
DATABASE GENBANK [online] 1 May 2002 (2002-05-01), STRAUSBERG R.L. ET AL.: "Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences", XP002981511, Database accession no. (BC028869) * |
DATABASE GENBANK [online] 10 July 2000 (2000-07-10), ADACHI J. ET AL.: "RIKEN functional annotation of a full-length mouse cDNA collection", XP002981507, Database accession no. (AK017880) * |
DATABASE GENBANK [online] 10 July 2000 (2000-07-10), ADACHI J. ET AL.: "RIKEN functional annotation of a full-length mouse cDNA collection", XP002981510, Database accession no. (AK009771) * |
DATABASE GENBANK [online] 10 July 2000 (2000-07-10), ADACHI J. ET AL.: "RIKEN Funtional annotation of a full-length mouse cDNA collection", XP002981505, Database accession no. (AK007787) * |
DATABASE GENBANK [online] 10 July 2000 (2000-07-10), Database accession no. (AK012437) * |
DATABASE GENBANK [online] 16 April 2002 (2002-04-16), Database accession no. (AK077118) * |
DATABASE GENBANK [online] 16 April 2002 (2002-04-16), Database accession no. (AK080754) * |
DATABASE GENBANK [online] 16 April 2002 (2002-04-16), Database accession no. (AK082963) * |
DATABASE GENBANK [online] 16 April 2002 (2002-04-16), Database accession no. (AK084668) * |
DATABASE GENBANK [online] 16 July 2001 (2001-07-16), ADACHI J. ET AL.: "RIKEN functional annotation of a full-length mouse cDNA collection", XP002981509, Database accession no. (AK030584) * |
DATABASE GENBANK [online] 16 July 2001 (2001-07-16), ADACHI J. ET AL.: "RIKEN functional annotation of a full-length mouse cDNA collection", XP002981512, Database accession no. (AK043006) * |
DATABASE GENBANK [online] 16 July 2001 (2001-07-16), Database accession no. (AK035957) * |
DATABASE GENBANK [online] 16 July 2002 (2002-07-16), Database accession no. (AK082495) * |
DATABASE GENBANK [online] 29 October 2001 (2001-10-29), STRAUSBERG R.L. ET AL.: "Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences", XP002981508, Database accession no. (BC016252) * |
DATABASE GENBANK [online] 4 September 2001 (2001-09-04), STRAUSBERG R.L. ET AL.: "Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences", XP002981506, Database accession no. (BC013497) * |
EMANUELSSON ET AL., J. MOL. BIOL., vol. 300, 2000, pages 1005 - 1016 |
ERDING HU ET AL.: "AdipoQ is a novel adipose-specific gene dysregulated in obesity", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 271, no. 18, 1996, pages 10697 - 10703, XP002096544 * |
ERDING HU, JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 271, no. 18, 1996, pages 10697 - 10703 |
GENOMICS, vol. 5, 1989, pages 874 - 879 |
HEIJNE, NUCL. ACIDS RES., vol. 14, 1986, pages 4683 |
J. SAMBROOK ET AL.: "Molecular Cloning", 1989, COLD SPRING HARBOR LAB. PRESS |
KAZUHISA MAEDA ET AL.: "Analysis of an expression profile of genes in the human adipose tissue", GENE, vol. 190, 1997, pages 227 - 235, XP002136672 * |
KAZUHISA MAEDA, GENE, vol. 190, 1997, pages 227 - 235 |
KEE-HONG KIM ET AL.: "A cysteine-rich adipose tissue-specific secretory factor inhibits adipocyte differentiation", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 276, no. 14, 2001, pages 11252 - 11256, XP002973338 * |
KEE-HONG KIM, JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 276, no. 14, 2001, pages 11252 - 11256 |
KISHIDA, K. ET AL., JOURNAL OF BIOLOGICAL CHEMISTRY (J. BIOL. CHEM., vol. 275, no. 27, 2000, pages 20896 - 20902 |
NAMBI, P. ET AL., JOURNAL OF BIOLOGICAL CHEMISTRY (J. BIOL. CHEM., vol. 267, 1992, pages 19555 - 19559 |
NATURE, vol. 411, no. 6836, 2001, pages 494 - 498 |
NUCLEIC ACIDS RES., vol. 29, no. 13, 2001, pages 2780 - 2788 |
PROC. NATL. ACAD. SCI. USA, vol. 98, no. 10, 2001, pages 5572 - 5577 |
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 86, 1989, pages 2766 - 2770 |
See also references of EP1541677A4 |
SYLVAIN BAULANDE ET AL.: "Adiponutrin, a transmembrane protein corresponding to a novel dietary- and obesity-linked mRNA specifically expressed in the adipose lineage", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 276, no. 36, 2001, pages 33336 - 33344, XP002973337 * |
SYLVAIN BAULANDE, JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 276, no. 36, 2001, pages 33336 - 33344 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7638270B2 (en) | 2003-01-24 | 2009-12-29 | Agensys, Inc. | Nucleic acids and corresponding proteins entitled 254P1D6B useful in treatment and detection of cancer |
US8460881B2 (en) | 2003-01-24 | 2013-06-11 | Agensys, Inc. | Nucleic acids and corresponding proteins entitled 254P1D6B useful in treatment and detection of cancer |
Also Published As
Publication number | Publication date |
---|---|
EP1541677A4 (en) | 2007-06-27 |
US20090203608A1 (en) | 2009-08-13 |
JP2008173122A (ja) | 2008-07-31 |
EP1541677A1 (en) | 2005-06-15 |
AU2003280992A1 (en) | 2004-02-02 |
US7833972B2 (en) | 2010-11-16 |
US20060110384A1 (en) | 2006-05-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2002112772A (ja) | 新規ポリペプチドおよびそのdna | |
WO2003099331A1 (fr) | Agents renforçateurs de la résistance à l'insuline | |
US7250272B2 (en) | G protein-coupled receptor protein and DNA thereof | |
WO2006068326A1 (ja) | 新規ポリペプチドおよびその用途 | |
US7833972B2 (en) | Proteins and use thereof | |
WO2003106683A1 (ja) | 新規スクリーニング方法 | |
WO2008038394A1 (fr) | Récepteur de la muscline et son utilisation | |
US7700361B2 (en) | Secretory or membrane protein expressed in skeletal muscles | |
WO2001046415A1 (fr) | Polypeptides de type tachykinine et utilisation associee | |
WO2004048565A1 (ja) | アポトーシス関連蛋白質およびその用途 | |
JP4169651B2 (ja) | 新規蛋白質およびその用途 | |
JP4542810B2 (ja) | 新規スクリーニング方法 | |
JP4559775B2 (ja) | 新規蛋白質 | |
WO2004097411A1 (ja) | 新規スクリーニング方法 | |
JP2004073182A (ja) | インスリン抵抗性改善剤 | |
JP4761812B2 (ja) | マスクリン受容体およびその用途 | |
JP4128030B2 (ja) | 新規リガンドおよびそのdna | |
JP2003315332A (ja) | スクリーニング方法 | |
WO2004022086A1 (ja) | 副腎皮質ホルモン分泌調節剤 | |
JP4004767B2 (ja) | 新規g蛋白質共役型レセプター蛋白質およびそのdna | |
JP2001299364A (ja) | 新規タンパク質およびそのdna | |
JP2004099490A (ja) | 新規スクリーニング方法 | |
JP2004083564A (ja) | 新規スクリーニング方法 | |
WO2002072816A1 (fr) | Proteine de recepteur murin de type kiss-1 et adn correspondant | |
JP2004166699A (ja) | 抗利尿剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2003741288 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2003741288 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2006110384 Country of ref document: US Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10520783 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWP | Wipo information: published in national office |
Ref document number: 10520783 Country of ref document: US |